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General Introduction and Outline of the Thesis
Adaptation of: 
Non-Muscle Invasive Bladder Cancer: an Update in Diagnosis, Treatment, and 
Prognosis
Tom J.H. Arends1, Eva Compérat2 and J. Alfred Witjes1
1Department of Urology, Radboud University Medical Center, Nijmegen, The 
Netherlands; 2Service d’Anatomie et Cytologie, Pathologiques Groupe Hospitalier 
Pitié-Salpêtrière, Paris, France
Journal of Oncopathology, 2013;3(13):51-63

11
General Introduction and Outline of the Thesis
Introduction
Bladder cancer (BC) is the second most common genitourinary malignancy 
worldwide. [1] In 2008 BC was the eighth most common cause for cancer 
specific mortality in Europe and the European Union age standardised mortality 
rate is 8 per 100.000 for men versus 3 per 100.000 for women. [2] Due to its 
high frequency, together with the relapsing nature of this disease, BC has a 
tremendous effect on our health care infrastructure. [3] About 75% of patients 
with BC present with non-muscle invasive BC (NMIBC). This category encloses 
BC that is confined to the mucosa (stage Ta and carcinoma in situ (CIS), figure 1) 
or sub mucosa of the bladder wall (stage T1, figure 1). To decrease pathological 
variability, the 1973 WHO grading classifications has been revised into the 2004 
WHO grading system (figure 2). [4, 5] In the current system the old grade 1 
tumours are divided in papillary urothelial neoplasms of low malignant potential 
(PUNLMP, a small minority) and low grade tumours (the vast majority). The 
old grade two tumours are divided in low and high grade tumours. [6] To date, 
Figure 1. Stages of bladder cancer
12
Chapter 1
the European NMIBC guideline advices to use both the 1973 and 2004 WHO 
classifications, since validation of the 2004 classification is ongoing and trials so 
far have conflicting results. [4, 7-11] How to diagnose and treat NMIBC, regarding 
the current guidelines and literature, will be elucidated in this chapter. The focus 
is exclusively on urothelial carcinoma’s (UC) since more than 90% of BC is of this 
origin.
Diagnosis
Symptoms and urothelial bladder carcinoma
Patients with NMIBC most often present with symptoms of (micro)hematuria 
and sometimes irritative voiding. Even though (micro)hematuria is one of 
the main symptoms in BC, it is certainly not specific as it appears in all kinds 
of uropathology like stone diseases, bladder infections, renal diseases, 
urinary traumata and systemic disorders (e.g. coagulation disorders). Because 
microhematuria mainly occurs without any other symptom, guidelines for the 
evaluation of asymptomatic microhematuria have been formulated by the 
American Urological Association (AUA) and their consensus is summarised 
in several articles.[12-15] In conclusion, long follow-up for adults with 
asymptomatic hematuria and negative urologic work-up is recommended. Even 
Figure 2. Comparison of the 1973 and 2004 WHO grading systems. [6] Adapted from 
Eur Urol. 2007;57:889-897; used with permission.
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for low risk patients (<40 years, non-smoking, no chemical exposure, no irritative 
voiding, no gross hematuria, no urologic history) a 3 year negative follow-up 
is advised. Noteworthy, these AUA recommendations are based on consensus, 
usual practice and expert opinion. Madeb et al. followed 234 microhematuric 
men without BC after urological work-up. Only two of the total cohort (0,85%) 
developed BC during 14 years of follow-up, respectively after 6.7 and 11.4 years, 
which suggests that idiopathic microhematuria has little chance of developing 
BC and appropriate follow-up may require reconsideration in light of these data. 
[16]
Cytology and urothelial bladder carcinoma
Urinary cytology has a significant share in the work-up for high-grade NMIBC. 
Urinary cytology evaluates the epithelial cells shed from the urinary tract for 
the presence of malignant cells from the urothelium. High-grade NMIBC usually 
results in positive urinary cytology and therefore its sensitivity and specificity are 
over 90%. [17] In contrast to cytology in high-grade tumours, its value is limited 
in patients with low-grade NMIBC. Due to the cytologic similarity of low grade 
malignant cells to normal urothelial cells in the urine, low grade tumours often 
show negative urinary cytology and are associated with low sensitivity levels of 
4-31%. [18] This is also reflected by the 2013 European Association of Urology 
(EAU) guideline on NMIBC, where cytology is reserved for high-grade tumours. 
[4] Thus, positive urinary cytology can indicate an urothelial tumour anywhere 
in the urinary tract, especially high-grade tumours. Negative cytology, however, 
does not exclude the presence of a urinary tumour.
Cystoscopy and urothelial bladder carcinoma
Cystoscopy is the flexible endoscopic evaluation of the urinary bladder through 
the urethra, and can be done on the outpatient clinic without any anaesthesia. 
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Diagnostic cystoscopy should be performed in all patients with symptoms that 
can suggest BC. Urologists should describe their cystoscopy accurate; containing 
at least site, size, number and appearance of the tumour. Additionally, the 
bladder wall, urethra and prostatic urethra in men should be a standard part of 
the cystoscopy report. [4] 
Furthermore, a bladder diagram is recommended to visualize the location of 
an abnormality in the bladder (figure 3). Only when a bladder tumour has been 
visualised in earlier imaging studies (e.g. CT-scan), cystoscopy could be omitted 
because the patient will undergo a transurethral resection (TURBT) anyway. 
[19] Although diagnostic cystoscopy is the cornerstone in the diagnosis of BC, 
residual or recurrent disease after initial TURBT can be as high as 55%. [20-
22] This indicates that the sensitivity of the standard white-light cystoscopy 
during TURBT is limited, mostly due to detection difficulties of multifocal BC 
with a normal white-light cystoscope. New techniques, such as photodynamic 
Figure 3. EAU Guidelines on Non-muscle-invasive bladder cancer, 2013. Example of a 
bladder diagram for cystoscopy. [4]
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diagnosis (PDD) and narrow-band imaging (NBI), can improve this diagnostic 
accuracy during TURBT, using other wavelengths of light, especially in CIS, where 
detection with normal white-light can be difficult because of its flat appearance.
PDD relies on violet light after intravesical instillation of 5-aminolevulinic acid 
(ALA) or hexaminolevulinic acid (HAL) and has been studied extensively. This 
preoperative instillation results in photosensitised malignant cells in a specific 
wavelength of light. White-light cystoscopy plus PDD improves tumour detection 
rates up to 90-96%; in contrast to white-light cystoscopy alone, which achieves 
73-96%. Especially in CIS, sensitivity rates improve from 23-68% in white-light 
cystoscopy alone, up to 91-97% in white-light cystoscopy plus PDD. [23-29] 
NBI uses the benefit of wavelength differences between normal urothelium 
and hypervascular BC-tissue. By filtering white light into two bandwidths this 
technique can better identify vessels which offers a higher sensitivity for detecting 
small papillary tumours and CIS, without any preoperative bladder instillation. 
A recent NBI meta-analysis, including 1022 patients in 8 studies, by Zheng et al. 
describes a pooled sensitivity and specificity of 94% (95%-Confidence Interval 
(CI): 91-96%) and 85% (95%-CI: 80-89%), respectively. For the characterization 
of CIS, the pooled sensitivity and specificity were 93% (95%-CI: 88-96%) and 77% 
(95%-CI: 73-80%), respectively. [30] This meta-analysis emphasizes the benefit 
of this method, resulting in higher diagnostic precision. The somewhat lower 
specificity is the result of inflammatory bladder tissue that resembles BC tissue 
and gives more false-positive biopsies. [31, 32]
Transurothral Resection
TURBT is the gold standard treatment in BC. During this procedure a rigid 
cystoscope, usually under spinal or general anaesthesia, is passed transurethrally 
into the bladder. A resectoscope is used to remove tumours by electrocautery or 
sharp dissection. The TURBT-procedure is essential to make the right diagnosis 
16
Chapter 1
and to eradicate BC as complete as possible, which is important for the prognosis 
of the patient. Absence of the detrusor muscle, the smooth muscle of the 
bladder wall for contraction during urination, is associated with a significantly 
higher risk of residual disease and early recurrence. [33] Furthermore, it has 
been elucidated that surgeon experience positively impacts TURBT results 
and therefore an adequate teaching program should be implemented in every 
teaching hospital. [34] Furthermore, a second TURBT can increase the recurrence 
free survival. [35] A second TURBT is recommended after an incomplete initial 
TURBT, if there was no detrusor muscle in the specimen, and in all pT1 and/
or grade 3 BC. The optimal timing for a second TURBT is not yet determined, 
however most urologists maintain a period of 2-6 weeks. [4]
Adjuvant Treatment
Based on stage, grade, CIS, earlier recurrences, number of tumours and tumour 
size we define three risk groups. The low risk group includes all BC with primary, 
solitary, Ta, G1 or low-grade tumours, with a diameter < 3 cm and no CIS. The 
high risk group has T1, grade 3 or high-grade, CIS, or multiple and recurrent and 
>3 cm Ta grade 1/grade 2 tumours. The intermediate group includes the rest 
(table 1) .
RISK GROUP DESCRIPTION
Low risk Primary, solitary, Ta, G1 or low-grade tumours, with a 
diameter < 3 cm and no CIS
Intermediate risk The rest
High risk T1, grade 3 or high-grade, CIS, or multiple and recurrent 
and > 3 cm Ta grade1/grade2 tumours
Table 1. Risk groups conform the EAU guideline 2013. [4]
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Low risk urothelial bladder carcinoma
Although TURBT is first standard of care in all BC, an immediate (within 24 hours) 
additional postoperative intravesical instillation is strongly recommended in 
low risk BC, because of circulating tumour cells resulting from TURBT and to 
realize an ablative effect on possible residual tumour at the resection site. 
[4, 36] Mitomycin, epirubicin and doxorubicin are the most commonly used 
agents for immediate intravesical instillation. The efficacy results of these three 
chemotherapeutic agents have not been studied in a comparative trial.  [37] 
Furthermore, there is no evidence that multiple adjuvant intravesical instillations 
give additional benefit in patients with low risk BC. [38]
Intermediate risk urothelial bladder carcinoma
In the intermediate risk group one immediate post-operative intravesical 
instillation of chemotherapy is insufficient, because of the higher chance of 
recurrence and progression. Therefore further adjuvant treatment is necessary. 
A large meta-analysis of 3703 patients showed a 44% reduction in recurrence 
at one year follow-up in favour of six times intravesical chemotherapy bladder 
instillations over TURBT alone. [39] Other data have demonstrated that one year 
of Bacillus Calmette-Guérin (BCG) therapy for the intermediate risk BC, is more 
effective in preventing tumour recurrence than six instillations of chemotherapy. 
[40-42] BCG, a live attenuated form of Mycobacterium bovis, triggers the immune 
system and has a local anti-tumour effect. The exact mechanism of its anti-
tumour effect, however, is still unknown. Although BCG has a better effect on 
recurrence rates in this risk group, one must consider and explain the significant 
increase in side-effects of BCG therapy (hepatitis, pneumonitis, disseminated 
tuberculosis) in relation to the relatively mild side-effects of chemotherapy.
18
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High risk urothelial bladder carcinoma
As mentioned before, re-TURBT in high risk BC after initial TURBT is important as 
residual tumour rates are as high as 55%. [20, 21] Moreover, adequate histological 
staging is very important for therapy planning and additional instillations are 
more effective if there is less/none residual tumour. [43] BCG immunotherapy is 
the instillation therapy of choice in high risk NMIBC. The optimal BCG schedule 
has yet to be determined. There is no level 1 evidence about the optimal 
number of instillations, nor about the optimal frequency and duration. [44] 
There is recent proof that three years of full dose maintenance BCG reduces the 
recurrence rate as compared to one year of one third dose maintenance BCG in 
high risk patients, but this benefit should be weighed against its added costs and 
complaints. [45]
Despite the use of adjuvant instillations, recurrences in NMIBC remain high. To 
date, there is an unmet need for patients who fail on BCG therapy. Failed BCG 
therapy is defined as muscle-invasive tumour after initiation of BCG, high-grade 
papillary NMIBC at 3 months, CIS at both three and six months. [4] No alternative 
treatment is recommended in the guidelines, except radical cystectomy. A 
substantial part of NMIBC patients, however, is unwilling or not fit to undergo 
this major type of surgery. For this category of NMIBC patients new effective and 
safe intravesical treatment options are highly needed
Outline of the Thesis
This thesis mainly focuses on new adjuvant intravesical therapies for NMIBC. 
In chapter 2 patient and tumour characteristics of patients treated with 
chemohyperthermia (CHT) were prospectively collected to evaluate the 
single centre recurrence-free survival (RFS) rate in this cohort of patients. The 
secondary objective was to compare CHT combined with Mitomycin (MMC) 
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vs. CHT combined with Epirubicin, and to evaluate the RFS in highly recurrent 
patients (>2 recurrences in 24 months) vs. the rest.
Although the use of CHT as an alternative treatment is expanding in Europe, to 
date, there is a lack of prospective randomised data to compare BCG with CHT 
therapy. Furthermore, at this very moment, there is a worldwide shortage of 
BCG, resulting in a tremendous adjuvant treatment dilemma for intermediate- 
and high risk NMIBC patients. In chapter 3 a randomised, controlled, open-label, 
multicentre trial is described in which the CHT effect is compared with BCG. RFS 
after 24 months in both groups was the primary objective in this study. Second, 
the proportion of complete response (CR) at three months in CIS patients, 
progression to muscle-invasive disease and/or metastatic disease, and safety of 
both treatments are described.
Despite the fact that the benefits of CHT have been confirmed by several 
studies, CHT response is not uniform. To date, the mode of action is still 
poorly understood. Urinary cytokines/chemokines after CHT might provide 
additional information to understand more of thermochemotherapeutically cell 
destruction. In chapter 4 an explorative study was conducted to identify changes 
in urinary cytokine/chemokine levels. Urinary cytokine/chemokine levels 
were collected longitudinally after CHT, and compared with levels of the same 
cytokines/chemokines in patients receiving cold-MMC instillations. The primary 
objective of this pilot study was to examine whether urinary levels of selected 
CK’s differed between CHT treated and cold-MMC treated patients. The second 
objective was to evaluate whether CHT responders could be distinguished from 
CHT non-responders based on their cytokine profile.
In chapter 5 the efficacy of the new intravesical agent TMX-101 is discussed in a 
multicentre, prospective phase I trial. TMX-101 is a part of the Toll like receptor 
(TLR) family, a conserved group of cell membrane proteins with a critical role in 
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antimicrobial immunity and the proteins are a key component of the immune 
system. Preclinical and clinical studies suggest the role of the TLR’s in modulating 
anti-tumour immunity. TLR-7 and TLR-8 are key targets of Aldara™ cream 
(imiquimod) for the treatment of basal cell carcinoma, actinic keratosis and 
genital warts. Imiquimod is contained in TMX-101, a new drug formulated for 
intravesical use with anti-proliferative effects against urothelial carcinoma as well 
as anti-tumour effects in preclinical research. The safety of TMX-101 in humans 
has already been described. In chapter 5 the ablative ability of TMX-101 in a 
marker lesion concept has been described. Furthermore the pharmacodynamic 
and pharmacokinetic characteristics of TMX-101 are discussed.
Chapter 6 provides a general discussion and the future perspectives.
A summery is provided in chapter 7.
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Abstract
Purpose
Non-muscle invasive bladder cancer (NMIBC) is characterized by high recurrence 
rates. New adjuvant treatments are needed to decrease this high number of 
recurrences. In this series the results of >10-years chemohyperthermia (C-HT) 
experience for NMIBC-patients are presented.
Materials & Methods
Patient and tumor characteristics of patients treated with C-HT between 2002 
and 2013 were prospectively collected using standardized medical record 
forms. Median follow-up was 75.6 months. Recurrence-free survival (RFS) was 
the primary objective. The secondary objective was to observe RFS differences 
in, 1) epirubicin(EPI)-group versus the mitomycin(MMC)-group, and 2) highly 
recurrent (>2 recurrences in 24 months) NMIBC-group versus the rest.
Results
160 NMIBC patients were included. Twenty (13%) patients were treated with 
EPI. 129 (81%) patients were previously treated with BCG. 1 and 2 years RFS was 
60% and 47%, respectively. In 4% muscle invasive progression was seen. Two-
year RFS in the EPI and MMC groups were 55% and 46%, respectively (p=0.30). 
The highly recurrent NMIBC group had a significant decreased RFS, compared 
to the rest (p<0.01). Patients with ≤2 TURBT’s compared to >2 TURBT’s before 
C-HT had a higher RFS (p=0.01). On multivariable analysis the highly recurrent 
NMIBC criteria remained independently associated with a decreased RFS (HR: 
2.40 (1.30-4.43), p=0.01).
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Conclusion
C-HT is an effective approach for NMIBC patients in which standard intravesical 
treatments fails. Patients with highly recurrent disease before C-HT have a 
lower RFS. Furthermore, RFS appears to improve with an earlier onset of C-HT. 
No significant differences were observed between the two chemotherapeutic 
agents.
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Introduction
Bladder cancer (BC) is the second most common genitourinary malignancy 
worldwide and has a great impact on our healthcare infrastructure and costs. 
[1, 2] Worldwide approximately 2.7 million patients have been diagnosed, 
treated and followed-up for BC at any given time point. [1, 3] Seventy-five 
percent of BC patients present with non-muscle-invasive BC (NMIBC). NMIBC is 
characterized by a high recurrence rate, which emphasizes the need for adjuvant 
intravesical therapies after transurethral resection (TURBT). To date, intravesical 
chemotherapy for low- and intermediate-risk tumors and intravesical Bacillus 
Calmette-Guerin (BCG)-therapy for intermediate and high-risk tumors are the 
gold standards. Despite adjuvant treatment, however, up to 61% of all patients 
will recur within one year. [4, 5] Particularly in patients with high risk NMIBC, the 
risk of progression also increases and due to the lack of alternative conservative 
treatments, this may result in early cystectomy.
Chemohyperthermia (C-HT) is an alternative treatment for patients in whom 
radical surgery is not an option due to co-morbidities, and for patients who 
refuse radical surgery and prefer conservative treatment in order to keep their 
bladder. As known from the literature, hyperthermia causes inhibition of DNA, 
RNA and protein synthesis. These changes may be lethal for the cell if repair 
mechanisms are not effective. [6, 7] Furthermore, the thermal effect provides 
better drug penetration into the bladder wall, which may potentially improve 
the drug effect on residual cancer cells at the base of the resected area. [8] 
A randomized controlled multicentre trial showed that (C-HT) results in lower 
recurrence rates, in comparison with chemotherapy alone (p=0.0002). [9] These 
C-HT advantages were reproduced in several other series, including different 
NMIBC risk groups. [10-12] After more than ten years of treatment experience, 
a monocentric series of C-HT for a group of patients, in which 96.3% had non-
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responding recurrent NMIBC, is presented.
Materials and methods
Cohort assembly and data collection
An institutional review board approved computerized database was reviewed 
including all patients (N=189) who received C-HT treatment between November 
2001 and January 2013. Clinical and histopathological data were prospectively 
collected during the years, and entered into an electronic database by two 
dedicated data extractors. If necessary, a retrospective medical record review 
was also performed. Files were missing of 29 patients. Indication for C-HT 
was NMIBC (N=160) refractory for regular intravesical treatment, of whom 
129 (80.6%) patients had previously failed on BCG therapy. Six patients (3.8%) 
received C-HT as first intravesical treatment, whereof four at their own request, 
and two in which the reason was not clearly documented. 
Treatment
The SB-TS 101 system (Synergo®, delivered by Medical Enterprises) was used to 
achieve local microwave induced hyperthermia and intravesical chemotherapy 
simultaneously. This system has a 915 MHz intravesical microwave applicator 
that delivers hyperthermia of the bladder wall. The applicator is on the tip of 
the specially designed 20 F transurethral catheter. [9] The catheter also contains 
5 thermocouples. Two thermocouples for temperature monitoring in the 
prostatic urethral tract; the other three for the posterior and lateral walls of the 
bladder. To avoid urethral overheating and disintegration of MMC, the solution 
is continuously pumped out of the bladder and re-instilled after being cooled. 
The treatment regimen could be adjuvant, after complete TURBT, or ablative. 
In either situation, the treatment consisted of 6 to 8 weekly sessions, followed 
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by maintenance sessions at 6-week intervals during the first year. According to 
previous published literature [13-15], patients in the adjuvant setting received 
20mg/50mL mitomycin (MMC), or 25 mg/50mL of epirubicin (EPI) in case of an 
MMC-allergy. In the ablative setting 40mg/50mL MMC was used, or 50mg/50mL 
EPI in case of MMC-allergy. Each treatment consisted of 2 consecutive 30-minute 
cycles with bladder wall hyperthermia to 42⁰C ± 2 ⁰C. Clinical complications and 
side effects were reported in the patient’s personal file.
Follow up and statistical analysis
Patients underwent routinely cystoscopy and cytology at a 3-month interval 
during the first year. In case of carcinoma in situ (CIS), biopsies were taken after 
the 6th treatment session. After the first recurrence-free year this interval could 
be extended, according to the expertise of the urologist. In case a patient had 
one low-grade recurrence during follow-up, this recurrence was resected and 
patient returned to treatment. These patients were counted as non-recurrent 
in the analyses, since these recurrences were of no clinical significant influence.
The primary objective was recurrence-free survival (RFS). The secondary 
objective was to observe a difference in RFS in 1) the EPI-group versus the MMC-
group and 2) the highly recurrent NMIBC-group (>2 recurrences in 24 months) 
versus the rest of the NMIBC patients, as described earlier by Nativ et al. [11] 
Kaplan-Meier plots were used to calculate RFS rates. The log rank test was used 
to compare subgroups. The Cox proportional hazard model was used to adjust for 
potential confounding variables. The Chi-Square test was used for the association 
between two categorical variables. Generalized estimating equation analysis was 
used to estimate the parameters with a possible unknown correlation between 
outcomes. All p-values reported are 2 sided; level of significance was p ≤ 0.05.
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Results
Descriptives
A total of 160 patients were included with a median age of 65 years (range 34-87 
years). Median follow up was 75.6 months. 75 patients (46.9%) had pT1 NMIBC 
and 85 (53.1%) had pTa NMIBC. 104 (65.0%) and 56 (35.0%) patients had high and 
low grade NMIBC, respectively. According to the EAU risk stratification criteria 
100 (62.5%), 60 (37.5%) and 0 (0%) patients were at high, intermediate and low 
risk, respectively. By means of the AUA guideline criteria, 153 patients (95.6%) 
had high risk NMIBC, and 7 patients (4.4%) low risk NMIBC. The mean number of 
treatments was 10.3 (range 2-37). Ten patients (6.3%) discontinued C-HT, due to 
side effects. Due to allergy for MMC 20 (12.5%) patients were treated with EPI. 
Mean number of TURBT’s before the start of C-HT was 5.9. In total 129 (80.6%) 
patients failed on BCG-therapy and 112 (70.0%) had highly recurrent disease 
before the start of C-HT. Nine patients (5.6%) had one low-grade recurrence 
during follow-up, which was resected and patients continued treatment. 
Hexaminolevulinate (HAL) TURBT was applied in seven (4.3%) patients prior to 
C-HT treatment. Baseline characteristics are listed in table 1.
Treatment results
Seven patients (4.3%) had progression to muscle-invasive disease. Six of them had 
a pT1GIII tumor before the start of C-HT, and three concomitant CIS. The initial 
complete response (CR) rate, defined as: no status of disease at cystoscopy or 
TURBT (in case of CIS) six weeks after the induction phase and negative cytology, 
in the ablative group was 77.5% (N=41). There were no statistically significant 
differences in CR rates between CIS-negative/CIS-positive patients, nor between 
pTa- /pT1-patients, nor between low-grade/high-grade patients (table 2).
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N=160 Number of patients (%)
Age
  ≤65
  >65
84 (52.5)
76 (47.5)
Gender
  Male
  Female
124 (77.5)
36 (22.5)
Before start C-HT treatment
Former intravesical treatment
  None
  MMC
  BCG
  MMC+BCG
  MMC+BCG+other
  Other
  Type of instillations unknown
6 (3.8)
8 (5.0)
51 (31.9)
74 (46.3)
4 (2.5)
2 (1.4)
15 (9.4)
Highly recurrent NMIBC*
  No
  Yes
  unknown
45 (28.1)
112 (70.0)
3 (1.9)
Amount TURBT 
  ≤2
  >2
23 (14.4)
137 (85.6)
Tumor grade 
  Low-grade
  High-grade
56 (35.0)
104 (65.0)
Tumor stage
  Ta
  T1
85 (53.1)
75 (46.9)
CIS
  Yes
  No
101 (63.1)
59 (36.9)
* Highly recurrent NMIBC =   
>2 recurrences/ 24 months.
Table 1. Baseline patient characteristics
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Table 2. Chi-square test for CR rate between subgroups
Analyzing all C-HT patients, the 1-year and 2-year RFS was 60% and 47%, 
respectively (table 3). Variables associated with decreased RFS in an univariable 
analyses were the amount of TURBT’s (≤2 vs. >2) and recurrence frequency 
(highly recurrent NMIBC vs. others). In patients with ≤ 2 TURBT’s before C-HT the 
2-year RFS was 71% compared to 42% in the >2 TURBT’s group (p=0.014, table 
3). In patients with highly recurrent NMIBC the 2-year RFS was 36% compared 
to 72% in the rest of the NMIBC-cohort. (p<0.001, figure 1 & table 3). In the 
EPI- and MMC-group the 1-year and 2-year RFS were 64% vs. 59% and 55% vs. 
46%, respectively (p=0.303, figure 2 & table 3). On multivariable analysis the 
recurrence frequency before C-HT remained independently associated with 
decreased RFS (HR: 2.40 (1.30-4.43), p= 0.005; table 4). 
Side effects
Adverse events were common, but mild, transient and mostly limited to the 
genitourinary tract. Endured side effects during treatment were recorded 
immediately after a treatment session. All side effects occurring after treatment 
were recorded during the next treatment session. Side effects were graded 
according to the Common Toxicity Criteria for Adverse Events (CTCAE) 4.0 
criteria. In the total of 1671 treatment sessions, 1979 adverse events (AE’s) were 
reported. Overall, 1912 (96.6%) AE’s were graded as 1 or 2. During treatment, 
bladder spasms and bladder pain were most often seen, respectively 23.3% and 
Subgroup CR rate p-value
CIS negative
CIS positive
75.0%
80.0%
0.71
pTa
pT1
84.6%
74.1%
0.46
Low-grade
High grade
88.9%
77.4%
0.35
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Figure 2. Recurrence-free survival stratified by chemotherapy.
Figure 1. Recurrence-free survival stratified by NMIBC recurrence frequency before 
C-HT.
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Table 3. Univariable analysis for recurrence-free survival
Probability of recurrence-free survival
1 years (95%-CI) 2 years (95%-CI) p-value
Total cohort (N=160) 59.5 (51.3-67.7) 47.0 (38.4-55.6)
Age
  ≤65years
  >65 years
59.3 (48.1-70.5)
59.8 (47.8-71.8)
46.5 (35.1-57.9)
47.5 (34.3-60.7)
0.74
Gender
  Male
  Female
59.9 (50.5-69.3)
58.5 (41.5-75.5)
44.7 (34.9-54.5)
54.9 (37.5-72.3)
0.53
History of CIS
  No
  Yes
62.9 (52.9-72.9)
53.5 (39.5-67.5)
50.9 (40.3-61.5)
39.2 (24.2-54.2)
0.23
TURBT amount
 ≤2 TURBT before Synergo 
 >2 TURBT before Synergo
78.0 (58.6-97.4)
56.8 (48.0-65.6)
70.9 (48.7-93.1)
42.3 (33.1-51.5)
0.01
T1 in histology before Synergo
  No
  Yes
67.2 (56.8-77.6)
49.5 (36.7-62.3
51.8 (40.4-63.2)
41.1 (28.1-54.1)
0.29
Highly recurrent NMIBC before Synergo
  No
  Yes
77.8 (64.8-90.8)
51.8 (41.8-61.8)
72.2 (57.8-86.6)
35.5 (25.3-45.7)
<0.01
Ablative or prophylactic treatment
  Prophylactic
  Ablative
60.1 (50.7-69.5)
58.4 (41.8-75.0)
47.6 (37.8-57.4)
44.9 (26.1-63.7)
0.37
Treated with EPI
  No
  Yes
58.9 (50.1-67.7)
63.6 (39.8-87.4)
45.9 (36.7-55.1)
54.5 (28.1-80.9)
0.30
High-grade/low-grade before Synergo
  Low-grade
  High-grade
66.8 (54.0-79.6)
55.3 (44.9-65.7)
54.4 (40.4-68.4)
42.6 (31.6-53.6)
0.29
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16.8% of all treatment sessions. After treatment, dysuria and frequency/urgency 
were mentioned most often, respectively in 22.6% and 27.3% (Table 5).
Generalized estimating equations analysis showed that spasms during treatment 
occurred significantly more in men than in women (OR = 2.36, 95%CI: [1.15 ; 
4.85], p = 0.019). This applies for induction phase and maintenance phase (OR = 
1.04, 95%CI: [0.86 ; 1.24], p = 0.706). No other AE did differ significantly between 
genders (data not shown).
Discussion
BC recurs in 61% of all NMIBC-patients within one year, despite adjuvant 
treatment. [4, 5] This recurrent tendency of NMIBC emphasizes the need for 
better, and if possible, safer treatments with new intravesical instillations. Due 
to the risk of progression and inherent decreased disease-specific survival, to 
date, the European Association of Urology (EAU) Guidelines on NMIBC strongly 
advice to consider a cystectomy in patients with BCG-refractory tumors. [16] 
However, cystectomy is major surgery with subsequent risks and complications. 
Moreover, since up to 70% of patients with NMIBC treated with BCG never 
progress to muscle-invasive disease, overtreatment in this group is significant. 
[17] As a consequence, successful and safe new treatment options that can help 
Table 4. Multivariable analysis for recurrence-free survival
Recurrence-free survival
Hazard ratio (95% CI) p-value
Age (>65 vs. ≤65) 0.93 (0.61-1.44) 0.76
Gender (Male vs. Female) 0.86 (0.51-1.43) 0.55
TURBT amount before C-HT (>2 vs. ≤2) 1.54 (0.62-3.85) 0.35
Chemotherapy (EPI vs. MMC) 0.62 (0.30-1.29) 0.20
Recurrence frequency before C-HT 
 (Highly recurrent vs. rest)
2.40 (1.30-4.43) 0.01
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Table 5. Adverse events stratified by common toxicity criteria severity 4.0
% Grade 1 % Grade 2 % Grade 3 % Total (N=1671)
Reported AE’s during induction-treatments
AE during treatment
  Pain 9.6 1.1 0.2 10.9
  Spasms 8.2 4.5 0.6 13.3
  Catheter problems 3.3 2.2 1.0 6.5
  AE after treatment
  Dysuria 12.0 3.0 0.0 15.0
  Hematuria 3.7 0.9 0.0 4.5
  Allergy 0.5 0.2 0.1 0.8
  Urinary tract infection 0.3 0.1 0.1 0.5
  Nocturia 2.6 1.3 0.5 4.5
  Incontinence 0.8 0.1 0.0 1.0
  Frequency/urgency 15.4 2.0 0.2 17.7
  Other 1.0 0.0 0.0 1.0
Reported AE’s during maintenance-treatments
AE during treatment
  Pain 5.5 0.3 0.1 5.9
  Spasms 5.9 3.5 0.5 10.0
  Catheter problems 2.2 0.7 0.4 3.3
AE after treatment
  Dysuria 6.2 1.3 0.1 7.6
  Hematuria 2.1 0.1 0.0 2.2
  Allergy 0.1 0.1 0.0 0.2
  Urinary tract infection 0.1 0.1 0.0 0.1
  Nocturia 1.7 1.0 0.0 2.8
  Incontinence 0.6 0.3 0.0 0.9
  Frequency/urgency 7.9 1.6 0.1 9.6
  Other 0.3 0.0 0.0 0.3
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in preserving the bladder in patients failing BCG are most welcome. Several 
new intravesical treatments are currently under investigations to evaluate their 
additional benefit in BCG-naïve patients and in patients in whom BCG failed. 
Even though several new therapies have been described, data are still limited 
and more results are needed. To date, Gemcitabine and BCG/IFN-α-2b series 
report results about their effect in BCG-failure patients, with a 19% and 45% 
RFS after two years, respectively. However, progression rates are up to 33%. 
[18, 19] In the current series, in which over 80% were previously treated with 
BCG, almost half of all C-HT patients had no evidence of disease after two years. 
Moreover, the progression rate was less than 5% during a 75.6 months median 
follow up.
The recurrence history of NMIBC appears to be of significant influence to the RFS, 
on univariable and multivariable analysis (highly recurrent vs. the rest; p<0.01, 
figure 1). The number of TURBT’s before C-HT was associated with the RFS on 
univariable analysis, however not on multivariable analysis. Since the mean 
number of TURBT’s before C-HT was close to six, the number of patients with 
≤2 TURBT’s before C-HT (N=23) is probably too low to detect an independent 
association between the amount of TURBT’s and the RFS. Even though, these 
data do univariably indicate a better outcome if C-HT is offered earlier to this 
group of non-responders, higher volumes are needed to specify this as an 
independent prognostic factor.
Reported AE’s of C-HT were common. However, they were generally reported 
as mild or moderate and resolved mainly without intervention. Patient drop-
out due to C-HT side effects is low. According to our data, bladder spasms do 
occur more in men, which can result in leakage of the chemotherapeutic agent. 
Prophylactic treatment with a muscarinic receptor antagonists, therefore, should 
be considered in men.
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Nativ et al. presented a 56% 2-year RFS in a retrospective group of 105 C-HT 
patients with a median follow up of 16 months. [11] So far, no other data have 
been published and high-volume prospective series are lacking. Nonetheless, a 
multicentre randomized controlled trial (www.clinicaltrials.gov: NCT00384891) 
comparing the efficacy and safety of C-HT vs. BCG is currently analyzing its last 
follow up, and results are expected shortly. To date, this is the largest C-HT group 
presented. Moreover, there is no published data on C-HT combined with EPI. 
Although, there were only 20 patients of the total cohort treated with EPI a, at 
least, similar RFS can be observed. However, numbers in this subgroup are small. 
In addition, no significant differences in side effects were observed between EPI 
and MMC application. 
Although we do know that better RFS can be observed with maintenance-
therapy, the duration and frequency is still unknown. [11] According to our 
growing experience, maintenance interval and cystoscopy/cytology follow up, 
has been extended after the first year of maintenance therapy. 
In our series no conclusions regarding the optimal maintenance scheme could be 
drawn due to the variation of the maintenance scheme. Nonetheless, with over 
more than ten years experience in our centre, long-term maintenance therapy 
is considered feasible, safe, without any observed increase of side effects and a 
relatively good long-standing RFS.
This study is subject to limitations, in particular the retrospective study design 
with subsequent risk of selection and information bias. Data of 29 cases were 
missing, negatively influencing the information bias. Obviously, data are still 
limited and more (prospective) research is needed. In addition we need to 
emphasize that these data do not yet show that hyperthermia is the treatment 
of choice after BCG-failure. The gold standard after BCG-failure still is radical 
cystectomy. Nonetheless, C-HT can certainly be considered in selected cases. 
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Conclusion
In light of these data C-HT seems to be an effective approach for NMIBC patients 
in which regular intravesical treatments fail. Better results are observed in 
patients without highly recurrent disease before C-HT. Furthermore, RFS appears 
to improve with an earlier onset of C-HT. Finally, results with MMC and EPI as 
chemotherapeutic agents were comparable. Prospective randomized multi-
centre trials are needed.
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Abstract
Background
Despite adjuvant intravesical therapy, recurrences in non-muscle invasive 
bladder cancer (NMIBC) are still high. Therefore, new treatment options are most 
needed. The use of chemohyperthermia  (CHT) as an alternative treatment is 
expanding in Europe. To date, however, there is a lack of prospective randomized 
data.
Objective
To compare CHT using Mitomycin-C (MMC) with BCG as atdjuvant treatment for 
intermediate- and high-risk NMIBC.
Design, setting, and participants
Between 2002 and 2012 190 NMIBC patients were randomised in this controlled, 
open-label, multicentre trial for 1-year CHT (6-weekly treatments and 6 
maintenance treatments) and 1-year BCG-immunotherapy (6-weekly treatments 
and 3 times 3-weekly maintenance treatments). Patients and physicians giving 
the interventions were aware of assignment. This study is registered with 
ClinicalTrials.gov: NCT00384891.
Outcome measurements and statistical analysis
The primary endpoint was the 24-months recurrence-free survival (RFS) in the 
Intention-To-Treat (ITT) and Per-Protocol (PP) analyses in all papillary NMIBC-
patients (N=147). Analyses are done by the logrank test and Fisher’s exact T-test 
in SAS v9.3. All tests were 2-sided.
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Results and limitations
The 24-months ITT-RFS was 78.1% in the CHT-group as compared to 64.8% in 
the BCG-group (p=0.08). The 24-months RFS in PP-analysis was 81.8% in the 
CHT-group, compared to 64.8% in the BCG-group (p=0.02). Progression-rates 
were <2% in both groups. Regarding the side-effects, no new safety concerns 
were identified. A concern is that this study closed preliminary, and thus is 
underpowered. Furthermore, blinding of treatment for patients and physicians 
was impossible, this may have resulted in unavoidable bias.
Conclusion
CHT is a safe and effective treatment option in patients with intermediate- and 
high-risk papillary NMIBC. A significantly higher 24-months RFS in the CHT-group 
was seen in the PP-analysis. Based on the results above, CHT is an option for 
BCG-therapy as adjuvant treatment for intermediate- and high-risk papillary 
NMIBC. 
Patient summary
Recurrences in NMIBC are common, despite adjuvant therapies. We compared 
the 24-months RFS of CHT therapy versus BCG therapy. According to these 
data, CHT therapy appears to be safe and has a higher 24-months RFS than BCG 
therapy.
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Introduction
Treatment strategies for intravesical therapy of non-muscle-invasive bladder 
cancer (NMIBC) have not changed significantly the past three decades. 
Intravesical irrigation is usually done with Mitomycin-C (MMC), Epirubicin 
and Valrubicin,. An upcoming agent is Gemcitabine, but is not considered 
standard yet. Besides chemotherapeutics, there is immunotherapy with Bacillus 
Calmette-Guérin (BCG) with a better efficacy than intravesical chemotherapy [1], 
but has more frequent and severe side-effects. Despite extensive research, no 
major changes have been realised in adjuvant treatment regimens , however, 
new drugs and strategies are currently studied. The combination of intravesical 
chemotherapy and hyperthermia by radiofrequency has been used in clinical 
practice for >15 years now, but experience remains limited, as are reported data. 
The first randomised controlled trial was published in 2003 [2] showing a clear 
advantage of CHT over treatment with MMC alone. This trial was updated in 
2010, resulting in similar conclusions. [3] A recent review evaluated the results 
of CHT with regard to recurrence and progression, including toxicity. [4] Since 
CHT is used in combination with MMC, this review focused on the comparison 
of CHT versus MMC alone. A reduction in recurrence-rates of 59% for CHT was 
found. Nevertheless, data were insufficient to make  statements on progression. 
Furthermore, CHT had more local toxicity and complications as compared to 
MMC alone, but differences were not significant. Lammers et al. concluded 
that, although this review showed a reduced recurrence-rate for CHT, more 
conclusions could not be drawn due to limited data from randomised trials and 
different design of studies. 
In this study, we report on the results  of intermediate- and high-risk NMIBC 
patients who were randomised between intravesical CHT with MMC and BCG.
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Methods
In this international multicentre prospective randomised phase III trial 11 
institutions participated from six different countries: Israel (N=3), Italy (N=3), 
the Netherlands (N=1), Austria (N=1), France (N=2) and Belgium (N=1). Ethical 
committee approval was obtained at all participating hospitals. The study was 
conducted in accordance with Good-Clinical-Practice, with the Declaration of 
Helsinki (version 1996) and with local laws and regulations. [5, 6] This study is 
registered with ClinicalTrials.gov; number: NCT00384891.
Patient selection
Patients with intermediate- and high-risk NMIBC according to the 2001 EAU 
risk-category definitions were eligible. [7] Inclusion criteria were patients with 
any pT1 or grade 3 urothelial carcinoma (UC) and/or carcinoma-in-situ (CIS); or 
multifocal (>6) pTa lesions and/or multiple (>3) recurrences of pTa-lesions in the 
last 24 months. All patients required a presumed transurethral resection of the 
bladder tumour (TUR),confirmed by negative cytology and video-cystoscopy 
with negative biopsies from suspected areas before intravesical therapy started. 
In high risk NMIBC-patients re-resection of the tumour bed and random biopsies 
were mandatory. In case of CIS-patients, positive cytology and/or CIS-positive 
biopsies were allowed. Further criteria were a WHO-performance status<2; a life 
expectancy>24 months; patients willing to sign informed-consent according to 
ICH/EU-GCP, and national/local regulations.
Exclusion criteria were histology other than UC; another primary malignancy 
(basal cell carcinoma excluded); UC involving the urethra or upper urinary tract; 
previous history of UC≥T2; intravesical MMC-treatments during the last 12 
months, any previous BCG-therapy <48 months; previous pelvic radiotherapy 
or systemic chemotherapy; partial cystectomy; bladder diverticulum >1 
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cm; residual urine>100cc; bladder volume<150cc; urinary incontinence; 
urethral stricture impeding 20F-catheterisation; persistent hematuria; active 
intractable/uncontrollable urinary tract infection (UTI); active tuberculosis/
BCG-infection; patients with previous BCG life-threatening sepsis; known MMC/
BCG allergy ; known impaired immune response, positive HIV-serology, patients 
receiving systemic steroids or immunosuppressives; haematological disorders; 
leukocytes<3500, platelets<100,000; kidney or liver function disorders (>1.5 
times upper normal limit), pregnant/lactating women. All patients gave written 
informed-consent. 
Treatment schedules
The hyperthermia device (Synergo®-System; Medical Enterprises Europe B.V.) 
has been described in detail before. [2] In summary: it is a computer-embedded 
intravesical irrigation system combined with an energy-delivering unit. The 
irrigation system has a disposable catheter system that delivers radiofrequency 
energy through an antenna. This system employs hyperthermia of the bladder 
wall induced by emission of radiofrequency energy, monitored by deployable 
thermocouples, combined with intravesical chemotherapy. The drug is cooled 
by a heat-exchanger in a continuously circulated closed circuit.
After randomisation, patients in group 1 were treated with intravesical CHT with 
MMC, weekly during 6 weeks, followed by 6 maintenance sessions at 6-week 
intervals during the rest of year 1. Sessions consisted of 2x30 minute treatments 
with 20mg of MMC (Kyowa) dissolved in 50mL distilled water combined with local 
hyperthermia at 42±2°C . In group 2 BCG (OncoTICE®, full dose) was given as a 1 
year schedule: 6-weekly induction sessions and 3-weekly repeated maintenance 
sessions at months 3, 6 and 12. Patients retained BCG in the bladder for 120 
minutes. Intravesical therapy started between 3-8 weeks after initial TUR, or 3-6 
weeks after the second TUR in case of high-risk tumours.
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Follow-up and evaluation of therapy
Patients’ follow-up was at least 24 months after randomisation at 3 month 
intervals, including blood and urine analysis, cytology, cystoscopy and biopsies 
of suspicious areas . 
Study termination was defined as adverse events (AE’s) causing treatment 
delay for ≥2 weeks or withdrawal of informed-consent. Patients with a tumour 
recurrence during the 12 months of treatment underwent presumed radical TUR 
and continued treatment as planned, unless this recurrence was T1G3 or muscle-
invasive. Patient with a second recurrence went off study, but were followed for 
at least 24 months.
Side-effects
AE’s (using Common-Toxicity-Criteria-of-Adverse-Events (CTCAE)2.0) were 
recorded at every treatment or follow-up visit. In case of side-effects no dosage 
modifications were allowed, only treatment delay. For CHT, in case of severe pain 
due to the heating an increased pump flow and/or reduction of radiofrequency 
power was applied. For other side-effects treatment recommendations were 
protocol given.
Objectives
The objective of this study was the comparison of intravesical CHT with MMC 
versus intravesical immunotherapy versus BCG for adjuvant treatment in patients 
with intermediate- and high-risk urothelial papillary NMIBC. The primary 
endpoint was recurrence-free survival (RFS) in the Intention-To-Treat (ITT) and 
Per-Protocol (PP)-analyses. Secondary endpoints were: Proportion of complete 
response (CR) in CIS-patients, progression to >T1 and/or metastatic disease, and 
safety of both treatments. CR in CIS-patients was defined as negative biopsies 
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and/or cytology at 3 months. 
Randomisation and statistical analyses
Patients were randomised with a 1:1 allocation ratio stratified by centre using 
the permuted block method. The randomisation assignment was placed in 
enumerated sealed envelopes which were kept by the secretary and only 
opened when a randomization form was received for a patient. A sample size 
was calculated to test the null hypothesis of equal RFS probabilities in both 
groups after 24 months with 80% power at a 5% level of significance. In previous 
studies with CHT treatment the 2-year recurrence rate was about 25%, and the 
previous published recurrence rate for BCG was 40%. Resulting in a total of 237 
NMIBC-patients. Expecting a 20% drop-out resulted in a target recruitment of 
300 patients, 150 in each group. 
Kaplan-Meier curves were constructed for each study arm. The null hypothesis 
was tested using the logrank Test.
Secondary endpoints are summarized by a count and percentage and compared 
between the groups with Fisher’s exact test. Safety results are presented in a 
forest plot portraying the odds ratio of each adverse event and 95% confidence 
interval with a reference line of no effect (odds ratio (OR)=1). Statistical analyses 
were performed with SAS V9.3. A p-value of ≤0.05 was considered statistically 
significant. This manuscript was conducted conform the CONSORT-guidelines.
Role of funding source
Medical Enterprises Europe B.V. provided financial support. No personal grants 
were provided. The corresponding author had full access to all data in the study 
and had final responsibility to submit for publication.
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Results
The trial was closed prematurely due to slow accrual December 31, 2011. 
Between 18 July 2002 and 25 December 2011 190 patients were included and 
randomised to CHT (N=92) or BCG (N=98). Of these 190 patients, 147 patients had 
pure papillary tumours (CHT-group 71; BCG-group 76) and 43 had (concomitant) 
CIS (CHT 21, BCG 22). 1 CIS-patient in the BCG-group received no treatment and 
was withdrawn owing to suspected tumour in upper urinary tract. Distribution 
of the different sites and the CONSORT-diagram is shown in Table 1. 
For safety analysis 184 (CHT-group 89; BCG-group 95) patients were available. 6 
patients did not receive instillations: in 2 patients the CHT-treatment was refused 
by the insurance company, in 2 patients protocol violations were noted before 
start of treatment (CHT-group 1; BCG-group 1), and 2 patients refused additional 
therapy after the TUR (both in the BCG-group). 
The ITT-analysis included all papillary NMIBC patients with at least 1 treatment 
given (N=142; 68 CHT-group, 74 in BCG-group). The PP-analysis included 132 
papillary NMIBC patients with at least 6 intravesical instillations as defined in 
the protocol (60 CHT-group, 72 BCG-group). In all 147 recruited papillary NMIBC 
patients 5 patients did not start therapy due to insurance issues (N=2, CHT-
group), consent withdrawn (N=2, BCG-group) and >T1 stage (N=1, CHT-group). 
In the PP-analysis an additional 10 patients had less than 6 treatments due to 
uncontrolled UTI (N=1, BCG), consent withdrawn (N=3; 2 CHT, 1 BCG), lost to 
follow-up (N=1; CHT), urethral bleeding (N=1; CHT), allergic reaction (N=1, CHT), 
concomitant squamous cell carcinoma (N=1; CHT), bladder diverticulae (N=1; 
CHT) and >T1 stage at revision of initial pathology report (N=1; CHT). Patient 
and tumour characteristics were comparable between treatment groups and are 
listed in Table 2. 
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Table 1. Distribution of RITE and BCG, papillary and CIS, in all participating sites and in a 
CONSORT diagram
Location
No. 
Patients
RITE
papillary
BCG
papillary
RITE
CIS
BCG
CIS
Jerusalem, Israel  4 2 1 0 1
Holon, Israel 12 6 5 0 1
Haifa, Israel 40 15 18 4 3
Paris, France  6 3 2 0 1
Milan, Italy 11 5 6 0 0
Milan, Italy 19 9 9 0 1
Lyons, France  3 0 3 0 0
Genoa, Italy 33 10 10 7 6
Nijmegen, The Netherlands 39 12 13 7 7
Brussels, Belgium 16 6 7 2 1
Vienna, Austria  7 3 2 1 1
TOTAL (11 centers) 190 71 76 21 22
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Table 2. Demographics and baseline characteristics (N=184)
BCG RITE
N= % N= %
Age, years- Mean (SD) 67.4 (10.08) 65.2 (10.67)
Gender
  Male
  Female
80
15
84.2
15.8
74
15
83.1
16.9
Stage
  Ta
  T1
41
42
49.4
50.6
34
42
44.7
55.3
Grade
  G1
  G2
  G3
16
34
33
19.3
41.0
39.7
14
27
35
18.4
35.5
46.1
Tumor size
  < 3cm
  ≥ 3cm
  Missing
68
26
1
71.6
27.4
  1.0
58
30
1
65.2
33.7
  1.1
Risk group
  High
  Intermediate
31
64
32.6
67.4
26
63
29.2
70.8
Risk group (without CIS)
  High
  Intermediate
10
64
13.5
86.5
5
63
  7.4 
92.6
CIS
  pure CIS
  papillary with CIS
12
9
57.1
42.9
13
8
61.9
38.1
Prior bladder instillations
  chemo (incl MMC)
  MMC
  BCG
8
6
4
44.4
33.3
22.3
13
6
6
52.0
24.0
24.0
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Efficacy
ITT-analysis papillary tumours
Median follow-up of the ITT-group was 25.6 months (range: 0.0 – 34.0). The 
24-months RFS was 78.1% (95% confidence-interval (95%CI):[65.2%;86.7%]) in 
the CHT-group as compared to 64.8% (95% CI:[52.2%;74.9%]) in the BCG-group 
(Figure 1, Table 3; p=0.08).
PP-analysis papillary tumours
Median follow-up of the PP-group was 25.3 months (range: 3.9-34.0 months). The 
24-months RFS was 81.8% (95%CI:[68.7%;89.8%]) in the CHT-group, compared 
to 64.8% (95%CI:[52.2%;74.9%]) in the BCG-group (Figure 1, Table 3; p=0.02).
CR-rate CIS-patients
The CR-rate of CIS-patients at 3 months patients was 88.9% in the CHT-group 
vs. 85.7% in the BCG-group. No statistically significant difference was observed 
(Fisher’s exact test, p=1).
Progression to muscle-invasive disease
In the CHT group 0 (0.0%) patients showed progression to muscle-invasive 
disease, compared to 1 (1.4%) in the BCG group. (Fisher’s exact test, p=1, Table 
3).
Safety
AE’s were recorded for patients with at least 1 treatment (N=184). In the CHT-
group: 1540 treatments were given in 90 patients and 1431 AE’s were observed. 
The most prevalent AE’s during treatment sessions were bladder spasms 
(N=206; 14.4%) and bladder pain (N=202, 14.1%). The most prevalent AE’s after 
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treatment were dysuria (N=167; 11.7%), nocturia (N=147; 10.3%) and urinary 
frequency (N=141; 9.9%). In the BCG-group: 1923 treatments were given in 94 
patients and 1525 AE’s were observed. The most prevalent AE’s in the BCG-
group were urinary frequency (N=274; 18.0%), dysuria (N=229; 15.0%), nocturia 
(N=227; 14.9%), hematuria (N=170; 11.2%) and fatigue (N=129; 8.5%). The CHT-
group had significantly less urinary frequency (odds ratio (OR): 0.61, 95%CI: 
0.49-0.75), nocturia (OR: 0.79, 95%CI: 0.63-0.98), incontinence (OR: 0.22, 95%CI: 
0.12-0.37), hematuria (OR: 0.56, 95%CI: 0.42-0.74), fever (OR: 0.09, 95%CI: 0.04-
0.10), fatigue (OR: 0.17, 95%CI: 0.11-0.28) and arthralgia (OR: 0.09, 95%CI: 0.03-
0.31) . However, catheterisation difficulties (OR: 16.7, 95%CI: 5.1-54.0), urethral 
strictures (OR: 2.3, 95%CI:1.3-4.1), bladder tissue reaction (OR: 5.8, 95%CI: 4.0-
8.3), bladder spasms (OR: 15.5, 95%CI: 9.7-25.0), bladder pain during sessions 
(OR: 26.3, 95%CI: 14.3-48.5), bladder pain in between sessions (OR: 1.6, 95%CI: 
1.2-2.3) and allergy (OR: 2.7, 95%CI: 1.6-4.6) were significantly more prevalent 
(Figure 2). Nine (probably) related serious AE’s were observed, five in the CHT-
group (contracted bladder, urethral bleeding, three fever) and four in the BCG-
group (retention, hematuria, UTI, fever).
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Figure 1. Kaplan-Meier curves of the recurrence rates in months for the CHT and BCG 
papillary NMIBC-groups (CIS excluded) in the ITT (a) and PP (b) efficacy analysis set.
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Discussion
Despite presumed complete TUR and adjuvant treatment, bladder cancer has 
a strong tendency to recur. Over 60% of all high-risk patients recur within 1 
year after diagnosis. [8, 9] New adjuvant therapies are therefore most needed. 
Several reports demonstrated the additional benefit of CHT, however most 
of these studies are weakened by retrospective design, no control group, no 
randomisation, or different MMC-concentrations between subgroups [3, 10-13]. 
Previously, 1 prospective, multicentre, randomised clinical trial was performed 
comparing CHT with MMC (42 patients) and MMC alone (41 patients) as 
adjuvant treatment after complete TUR. The recurrence-rate in the CHT-group 
was significantly lower in comparison to the MMC group; 17,1% vs. 57.3%, 
respectively (p=0.002). [2] Lammers et al. performed a meta-analysis in 2011 and 
found a 59.0% relative decrease in recurrences after CHT with MMC compared to 
MMC alone. [4] However, follow-up was too short to draw any other meaningful 
conclusions. 
Figure 2. Odds Ratios and 95% confidence intervals of adverse events at a log10-scale.
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Table 3. Efficacy data summarized *Confidence-Interval
ITT-analysis PP-analysis
Median follow up (95%CI*) (months) 25.6 (0.0-34.0) 25.3 (3.9-34.0)
24months RFS C-HT (95%CI) 78.1% (65.2-86.7) 81.8 (68.7-89.8)
24months RFS BCG (95%CI) 64.8 (52.2-74.9) 64.8 (52.2-74.9)
24months PFS C-HT 100.0% 100.0%
24months PFS BCG 98.6% 98.6%
Until now, no prospective data were available comparing CHT- with BCG-therapy. 
In the PP-analysis the 24-months RFS was significantly higher in the CHT-group 
compared to the BCG-group. The ITT-analysis also showed a difference in RFS in 
favour of CHT-therapy, however no statistical significance was achieved. 
In view of the recent worldwide shortages of BCG, this randomised controlled 
trial shows results that offer a reliable alternative with at least similar RFS-rates 
in comparison with BCG treatment. Consequently, future shortages could be 
(partly) countered with adjuvant CHT therapy for intermediate- and high-risk 
papillary NMIBC patients.
The CR-rate for CIS-patients did not significantly differ between the 2 groups. 
These findings, however, should be put into perspective. When this trial was 
started, the need for a different treatment strategy in case of ablative treatment 
(as used in CIS) compared to prophylactic treatment (as used in papillary tumours 
after TUR) was not clear. The first series showing that ablative treatment for 
CIS requires higher concentrations of MMC was from 2004. [14] We chose not 
to amend this study since primary endpoint was set for papillary tumours. 
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Furthermore, we now know that ideal BCG treatment for CIS requires three years 
full-dose maintenance instead of one year, as in this study was applied. [15] 
During the conduct of this study, there was no consensus regarding the optimal 
BCG-treatment schedule, nor clear advise in the European guidelines. Despite 
several series, the optimal BCG-maintenance schedule is still unknown. High-
risk NMIBC-disease currently requires at least one year of full-dose maintenance 
BCG; and three years maintenance, as well as adjustment of the dose, might be 
considered.
The rates of progression to muscle-invasive disease are surprisingly low in 
comparison to previous studies. [16] These results can only partly be explained. 
One of the possible reasons could be the relatively short follow-up in this study. 
Patients with progression after the 24-months of follow-up were not included in 
these analyses. 
Regarding the safety data of this report, no unexpected AE’s or new safety 
concerns were observed in the CHT- or BCG-group in comparison to previous 
literature. [4, 16-18] In general, systemic symptoms (arthralgia, fever and fatigue) 
and urinary incontinence were more frequent in the BCG-group, whereas local 
problems, such as bladder pain, spasms and urethral strictures were more 
frequent in the CHT-group.
This study is subject to limitations. A major concern is that this study closed 
preliminary, and thus is underpowered. Furthermore, blinding of treatment for 
patients and physicians was impossible, this may have resulted in unavoidable 
bias.
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Conclusion
CHT is a safe and effective treatment option in patients with intermediate- and 
high-risk papillary NMIBC. These data suggest that CHT-therapy is more effective, 
than BCG-therapy. According to the results above and the recent worldwide 
shortages of BCG, urologists might consider CHT as an option instead of BCG-
therapy as adjuvant treatment for papillary intermediate- and high-risk NMIBC. 
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Abstract
Objectives
To explore whether urinary cytokine and chemokine (CK) levels differed between 
cold Mitomycin-C (cold-MMC) treated patients and chemohyperthermia (CHT) 
treated patients, to shed light on the possible molecular mechanisms that might 
explain the superior outcome of CHT. Furthermore, CK-differences were explored 
between CHT responders and CHT non-responders. 
Methods
12 NMIBC-patients were included. Nine received six-weekly CHT and three four-
weekly cold-MMC instillations. Urine was collected on 8-12 time points before 
and after every treatment. MDC, IL-2, IL-6, IL-8, IP-10, MCP-1 and RANTES were 
determined by Luminex®-analysis. 
Results
Elevated urinary CK levels were observed in both groups after treatment. In 
general, CK-peaks were lower in the cold-MMC group in comparison with levels 
in the CHT group. Significant higher MCP-1 and IL-6 levels were observed in CHT 
treated patients. Additionally, significant cumulative effects were observed for 
IP-10 and IL-2. However, IP-10 and IL-2 levels did not significantly differ between 
treatments. MDC levels after the first week of treatment were significantly 
higher in the CHT responders compared with non-responders.
Conclusion
MMC-treatment leads to elevated urinary CK levels with significantly higher 
MCP-1 and IL-6 levels in CHT treated patients.  Increased MDC levels after the 
first CHT instillation appears to be related to good clinical outcome, and might 
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be of additional value to personalize treatment. Studies involving more patients 
and longer follow-up are needed to substantiate this observation.
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Introduction
Bladder cancer (BC) is the second most common genitourinary malignancy 
worldwide with a significant impact on healthcare infrastructure and costs. [1, 2] 
The estimated BC population is approximately 2.7 million patients worldwide. [1, 
3] Seventy-five percent of these patients present with non-muscle-invasive BC 
(NMIBC). NMIBC is characterized by a high recurrence rate, which emphasizes the 
need for adjuvant intravesical therapies after transurethral resection (TURBT). 
Despite adjuvant intravesical chemotherapy or immunotherapy, NMIBC recurs 
in almost two thirds of all patients within one year. [4, 5] Combined bladder 
wall hyperthermia and intravesical chemotherapy (Chemohyperthermia (CHT)) 
is an alternative treatment for this group of patients with recurrent NMIBC. [6] 
In a multicentre randomized controlled trial (RCT) CHT results were superior to 
chemotherapy alone with lower recurrence-rates, (p=0.002). [7] The benefits 
of CHT over cold-MMC alone have been confirmed by several studies in which 
different NMIBC subgroups were included. [8-10] Nevertheless, CHT response 
is not uniform, and biomarkers that could distinguish and stratify patients 
according to response would be of great value and pave the way to personalize 
treatment. 
Urinary IL-2 levels closely correlate to bacillus Calmette-Guerin (BCG) response. 
[11] Similarly, urinary cytokine/chemokine (CK) levels after CHT might provide 
the possibility to monitor the effects of the thermochemotherapeutically 
induced cell destruction. [12, 13] Thus, CK levels may provide qualitative, or 
possibly even quantitative information that allows CHT response monitoring. We 
conducted an explorative study to identify changes in CK levels in urine collected 
longitudinally after CHT in patients treated for recurrent NMIBC, and compared 
these with CK levels of patients receiving chemotherapy alone. The primary 
objective of this pilot study was to examine whether urinary levels of selected 
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CK’s differed between CHT treated and cold-MMC treated patients. The second 
objective was to evaluate whether CHT responders could be distinguished from 
CHT non-responders based on their cytokine profile.
C-HT group cold-MMC group
N (%) N (%)
Gender
  Male
  Female
7
2
(77.8)
(22.2)
3
0
(100.0)
(0.0)
CIS
  Positive
  Negative
6
3
(66.7)
(33.3)
0
3
(0.0)
(100.0)
Tumour grade
  Low-grade
  High-grade 
2
7
(77.8)
(22.2)
3
0
(100.0)
(0.0)
Tumour stage
  Ta
  T1
2
7
(22.2)
(77.8)
3
0
(100.0)
(0.0)
Cystitis
  No
  Yes
9
0
(100.0)
(0.0)
3
0
(100.0)
(0.0)
Recurrent NNMIBC
  No
  Yes
0
9
(100.0)
(0.0)
0
3
(0.0)
(100.0)
Prior instillations
  None
  MMC
  BCG
  MMC+BCG
1
0
3
5
(11.1)
(0.0)
(33.3)
(55.6)
0
3
0
0
(0.0)
(100.0)
(0.0)
(0.0)
Last TURBT*
  ≤ 6 weeks
  > 6 weeks
  Unknown
4
4
1
(44.4)
(44.4)
(11.2)
3
0
0
(100.0)
(0.0)
(0.0)
* last TURBT procedure before study entry
Table 1. Baseline patient characteristics (N=12)
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Materials and Methods
Patient assembly and urine collection
After approval of the institutional review board nine multiple recurrent NMIBC 
patients, starting their first CHT, were included between September 2009 and 
November 2012. All patients gave their informed consent prior to their inclusion 
in the study. Patients were tested for cystitis before treatment by dipstick and 
urinary culture. Urine was collected before every CHT, and 2-4, 4-6, 6-8, 8-12, 
12-24 and 96-108 hours after treatment. Additionally, urine was collected at 48-
60, 72-84, 120-132 and 144-156 hours after CHT exposure after the first and 
last treatment session. As a control group, three multiple recurrent NMIBC 
patients receiving cold Mitomycin-C (MMC) instillations for four consecutive 
weeks were included. Urine collection was as described above. Samples were 
immediately frozen to -20 degrees Celsius. Afterwards, specimens were thawed 
to four degrees Celsius, centrifuged, and stored in aliquots at -20 degrees Celsius 
in anticipation of analysis. Biopsies of the bladder wall were taken in all patients 
after the completion of six treatments. Baseline characteristics of the total 
cohort are listed in table 1.
Treatment procedure
The SB-TS 101 system was used to achieve local microwave induced hyperthermia 
and intravesical chemotherapy simultaneously. This system has a 915 MHz 
intravesical microwave applicator that delivers hyperthermia to the bladder 
wall. The applicator is on the tip of a specially designed 20 F transurethral 
catheter. [7] The catheter encloses 5 thermocouples: two thermocouples for the 
temperature in the prostatic urethral tract; the other three for the posterior and 
lateral walls of the bladder. To avoid urethral overheating and disintegration of 
MMC, the solution is continuously pumped out of the bladder and re-instilled 
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after cooling. Patients received 20mg/50mL MMC. One CHT patient switched to 
epirubicin 25mg/50ml after the third instillation, due to MMC allergy. However, 
since epirubicin has the same working mechanism as MMC and epirubicin-
induced cytokine profiles remained similar to MMC-induced profiles, this patient 
was not excluded from the study. Each CHT treatment included two consecutive 
30-minute cycles and bladder wall hyperthermia to 42⁰C ± 2 ⁰C. Cold-MMC was 
instilled by catheter for one hour.
Cytokine/chemokine determination
Five mixed test-samples of three patients each were tested for 22 CK’s. Based 
on these test results and previously published literature three cytokines 
(interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-8 (IL-8)) and four chemokines 
(macrophage-derived chemokine (MDC), interferon gamma-induced protein-10 
(IP-10), monocyte chemotactic protein-1 (MCP-1) and regulated on activation 
normal T-cell expressed and secreted (RANTES)) were selected for further 
analysis. [11, 14-16] Aliquots were tested by Luminex®-assay according to the 
manufacturers’ instructions. Urine was diluted eight times before testing. CK 
values were standardized to urinary creatinine, to correct for the hydration 
status of a patient. [11] 
Statistical analysis
The pattern of highest peak level after each treatment session of a CK of an 
individual was defined as the individual peak profile of that CK parameter. Linear 
mixed models for repeated measurements were used to study differences 
between the CHT and the cold-MMC group in the CK peak profile, for each 
CK parameter separately. The dependent variable was the peak value of the 
specific CK parameter. The independent class variable was the group (two 
levels: CHT and cold-MMC). The independent continuous variable was time 
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(weeks). The interaction term between time and group was also included in 
the linear part of the model. We found that this term never reached the level 
of statistical significance and was therefore omitted from the final model. The 
variable time was used to indicate the repeated measurements of each patient. 
Figure 1A.The observed mean of CK values in the entire period of treatment in the 
C-HT (gray bar) and cold-MMC (white bar) group. The vertical lines indicate (±) one 
standard error of the mean. Note the different scales for the left and right panel. 
Figure 1B: CK levels in urines collected during the entire treatment period of three 
representative patients. Patient 3 and 5 received C-HT, patient 12 received regular  
cold-MMC.
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The estimated difference in intercept between the groups and the increase 
per week (regression) of the mean CK profile in each group is presented with 
the appropriate 95% confidence interval. A T-test was used to test differences 
between CHT responders and CHT non-responders in peak concentration after 
Figure 2. The estimated regression parameters of the mean profiles of the CK 
parameters using linear mixed models for repeated measurements. Red line = C-HT 
group, blue line = cold-MMC group. The dashed lines indicate the 95% confidence-
intervals.
CK’s
Difference between C-HT and 
cold-MMC (µgr/ml) [95% CI]  p-value Increase per week [95% CI] p-value
MDC 10.75 [-1.92-23.41] 0.092 2.97 [-0.96-6.89] 0.133
MCP-1 121.27 [0.58-241.95] 0.049 10.56 [-31.39-52.50] 0.615
IL-2 0.12 [-0.06-0.30] 0.184 0.09 [0.01-0.16] 0.023
IL-6 6.81 [0.64-12.98] 0.032 0.00 [-1.86-1.87] 0.998
IL-8 314.54 [-17.45-646.53] 0.062 -13.37 [-106.50-79.75] 0.776
IP-10 100.29 [-121.20-321.77] 0.348 193.96 [109.96-277.96] <0.001
RANTES 37.53 [-0.13-75.19] 0.051 -3.29 [-9.53-2.95] 0.285
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the first CHT instillation. “CHT responder” was defined as: no tumour in the 
pathology report after six CHT sessions. Statistical analyses were performed 
using SPSSÒ 20 for Windows. P<0.05 was considered significant. 
Results
Mean patient age was 69 (range: 60-81) in the CHT treated group and 59 
(range: 55-66) in the cold-MMC treated group. In total 538/624 (86.2%) of 
expected urine samples were collected. 86 samples were lost due to freezing 
problems, patients inadequacy or lost to follow-up arguments. The mean CK 
values corrected for creatinine during the complete duration of treatment are 
shown in figure 1A. Figure 1B shows CK levels of three representative patients 
treated with CHT or cold-MMC. Increased CK levels were observed after every 
treatment exposure, regardless of treatment regimen. Baseline CK levels did not 
statistically differ between the CHT and the cold-MMC group (data not shown). 
Figure 2 shows the estimated mean profiles of CK peak concentration per group, 
including the 95% confidence-intervals. In general, the CHT CK peak levels were 
Figure 3. Box plot of MDC peak-concentration of C-HT responders (N = 4) and C-HT 
non-responders (N = 5) after the first instillation. C-HT responder = no tumor in the 
pathology report after six C-HT sessions. The mean MDC peak-concentration of C-HT 
responders was statistically significantly higher compared to the C-HT non-responder 
group (t-test, p = 0.005).
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higher in comparison to the peak levels in the cold-MMC treatment group. An 
observational trend of cumulative effects was seen for MDC, MCP-1, IL-2 and IP-
10. Significantly higher levels of MCP-1 and IL-6 were observed in the CHT group 
compared to the cold-MMC group (p=0.049 and p=0.032, respectively; figure 2). 
A borderline-significant difference was seen for IL-8 and RANTES (p=0.062 and 
p=0.051, respectively; figure 2). 
IP-10 (103.96, 95%CI [109.96-277.96]; p<0.001. figure 2) and IL-2 levels (0.09, 
95%CI [0.01-0.16]; p=0.023. figure 2) significantly increased per week, but IP-10 
and IL-2 levels did not significantly differ between the CHT and cold-MMC groups 
(IP-10: 100.29 [-121.20-321.77]; IL-2: 0.12 [-0.06-0.30], figure 2). The CK increase 
per week was never statistically significantly different between treatment groups 
for any of the CK determined.
Because the initial response might be indicative for the treatment effect, we 
investigated whether CHT responders (N=4) could be distinguished from CHT 
non-responders (N=5) based on cytokine concentration peak levels in the first 
week. The MDC peak concentration levels during the first week were significantly 
higher in the CHT responders compared to the CHT non-responders (median 24.9 
[p5-p95: 12.5-30.1] and 0.0 [p5-p95: 0.0-13.9], respectively; p=0.005, figure 3). 
None of the other CK investigated were significantly different in the first week, 
nor at any other period of time (data not shown).
Discussion
CHT is currently considered an experimental therapy for NMIBC patients. 
Despite evidence, including a RCT, that CHT can be beneficial when other 
intravesical treatments fail, up to now no guideline entitles CHT as a regular 
adjuvant therapy. [7-10, 17, 18] To date, cystoscopy combined with cytology, 
or biopsies in doubtful cases, are needed to confirm the clinical response after 
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intravesical therapy, including CHT treatment. The accompanying risks of these 
interventions are self-evident. Therefore, as is true for every monitoring, a 
predictive biomarker that can be measured non-invasively is of great importance. 
We show in this explorative study that CK levels in the urine of patients treated 
with CHT significantly differ from levels present in patients treated with cold-
MMC. Both MCP-1 and IL-6 were present at significantly higher levels in the CHT 
treated patients throughout the treatment, in comparison with the cold-MMC 
treated patients. Moreover, our results suggest that high MDC levels in the first 
week of treatment may predict a favourable CHT response. 
The observation that CHT appears to induce high IL-6 levels is of interest 
because antitumor activity of IL-6 in BC has been described in vitro and in vivo 
[19, 20]: xenograft animal studies indicate that the over expression of the IL-6 
down-regulates tumour genesis of bladder cells and IL-6 knockdown reverses 
this effect. Therefore it is possible that the improved therapy outcome in CHT 
is the result of the significant higher urinary IL-6 levels. MCP-1 is produced by 
a several cell types, including macrophages, and is involved in the recruitment 
of monocytes, T-cells and dendritic cells to sites of tissue injury. [21, 22] Limited 
evidence suggests that higher levels of MCP-1 are associated with increased 
antitumor effects in NMIBC patients. [23] The significantly higher MCP-1 and IL-6 
levels might be the consequence of more cellular damage after CHT treatment 
as a response to the warm MMC exposure and this might (partly) explain 
the favourable clinical benefit of CHT therapy in general.  Although objective 
evidence is missing, the better therapy outcome of CHT is thought to be caused 
by the deeper penetration of MMC due to the concurrent hyperthermia leading 
to increased cell death and therefore higher cytokine release. [10, 24] Data of 
the current study support this concept. As a spin-off to this concept, one could 
consider alternating therapies with CHT and BCG immunotherapy to increase 
cytokine release by CHT therapy and improve outcome results by consecutive 
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BCG immunotherapy. Although, previous studies with alternating cold-MMC 
treatment and BCG treatment did not show any significant benefit [25], 
combining CHT and BCG could be of interest. 
MDC peak levels during the first week of treatment were significantly higher in 
the CHT responding patients as compared to the non-responding CHT patients. 
This might be a reflection of more cellular damage, leading to a higher efficacy. 
Clearly, a reliable predictive urinary biomarker for CHT would be of great value 
because early termination of treatment in non-responding patients could 
be realized, saving unwanted drug expense and loss of quality of life without 
pathologic or cystoscopic confirmation. Whether the observed difference in 
MDC peak levels can reliably predict direct CHT outcome needs further study 
since the number of patients studied is very limited. Unfortunately, the number 
of patients in this pilot study is too small for any statement about the duration 
of response for those patients with high MDC peak levels during the first week.
Urinary levels of TNF-α, IFN-γ, IL-8, and in particular IL-2, appear to be associated 
with BCG therapy, the initial standard therapy for intermediate and high risk 
NMIBC patients [11, 15, 16, 26]. In our study we identified other CK that appeared 
to discriminate CHT responders from CHT non-responders. Most notably MDC 
was identified as a possible predictive biomarker. BCG treatment is based on 
immunological mechanisms, whereas the effect of MMC is based on the DNA 
cross linking ability, leading to cell death. In view of the different mechanisms 
involved in both therapies it is not unexpected that different CK profiles were 
observed.
Nonetheless, we observed accumulation of IL-2; similar to BCG [11]. However, 
whereas urinary IL-2 levels seem to be the most potent marker to predict BCG 
treatment response [26], IL-2 levels did not predict CHT response. Moreover, 
urinary IL-8 levels were higher in CHT treated patients, although this difference 
82
Chapter 4
was not significant. Elevated urinary IL-8 levels have also been associated with 
BCG therapy outcome. The cumulative effect of IL-2 and, albeit not significant, 
higher IL-8 levels in urine collected after CHT, suggest that immune mechanisms 
may play a role in CHT treatment as well. 
This study is subject to limitations. Despite the >500 collected urines, the 
number of included patients is low and stage/grade differences are present 
between the two groups. Furthermore, follow-up data could not be analyzed in 
this explorative study due to the low number of patients. Consequently to the 
above standing limitations, results should be interpreted with caution.
Conclusion
Urinary CK levels are elevated after MMC-treatment. Significant higher levels of 
MCP-1 and IL-6, and a borderline-significant concentration difference of IL-8 and 
RANTES were observed in CHT treated patients. IL-2 and IP10 show a significant 
cumulative effect. However, these cumulative effects were not significantly 
different between the two treatment groups. MDC increase after the first CHT 
instillation appears to correlate with favourable clinical outcome, and might be 
of additional value to personalize treatment. Further studies involving more 
patients and longer follow-up are needed to substantiate this observation.
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The Effect of TMX-101, a Phase 1 Trial
Abstract
Purpose
Non-muscle invasive bladder cancer (NMIBC) has a strong tendency to recur 
despite adjuvant instillations. TMX-101 is a new liquid form of imiquimod for 
intravesical instillation and has activity in-vitro against urothelial carcinoma. 
The purpose was to analyze the activity of TMX-101 in low-grade NMIBC. 
Furthermore, pharmacokinetic (PK), pharmacodynamic (PD) characteristics and 
adverse events (AE’s) were evaluated.
Materials & Methods
A multicenter, prospective phase I trial in seven low-grade NMIBC patients was 
conducted. All patients underwent a marker-lesion transurethral resection of the 
bladder tumor(TURBT) and six weekly instillations with TMX-101 0.2% or 0.4%. 
Cystoscopy 2-4 weeks after the last instillation evaluated the effect of TMX-101.
Results
The effective biological dose (EBD=complete response (CR) in >2 patients) 
could not be defined as none of the patients achieved CR. Maximum plasma 
concentration was 75.1 ng/ml in the 0.4% dose group. No drug accumulation 
was observed. In the PD-analysis, urinary IL-1ra represents the most sensitive 
and uniform response after TMX-101 instillation. 87.0% reported at least one 
AE. All events were of ≤grade 2 severity (CTCAE 4.02). No clinically significant 
changes in laboratory parameters and/or vital signs were observed, during or 
after treatment. 
Conclusions
Toll Like Receptor 7 (TLR-7) agonists are effective in urothelial carcinoma in 
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preclinical research. The EBD in this phase I study could not be determined 
because no patient achieved CR. IL-1ra could be valuable as urinary biomarker in 
future developments. The safety of TMX-101 has been reconfirmed. New doses, 
other schedules and NMIBC-subgroups, should be tested to define the EBD. A 
pilot study in CIS-patients is currently ongoing and results are expected shortly.
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Introduction
Bladder cancer (BC) has a significant burden on healthcare infrastructure and is 
one of the most expensive cancers per patient, mainly as a result of its relapsing 
nature.  [1, 2] Approximately 75% of all BC patients present with NMIBC. [3] 
Transurethral Resection of the Bladder Tumor (TURBT) is the gold standard of 
treatment of NMIBC. 
Adjuvant intravesical treatment depends on the risk group; in low-risk patients 
a single postoperative intravesical instillation with chemotherapy is sufficient. 
While in intermediate-risk patients consecutive instillations with chemotherapy 
or bacillus Calmette-Guerin (BCG) are required, and long-term BCG-treatment 
is needed in high-risk patients. [3] Despite these adjuvant treatments, NMIBC 
has a strong tendency to recur and therefore long and frequent follow-up is 
inevitable. Consequently, more effective treatments with fewer adverse events 
(AE’s) are most welcome.
The Toll Like Receptor (TLR) family is a conserved group of cell membrane 
proteins with a critical role in antimicrobial immunity and the proteins are a 
key component of the immune system. Receptor activation results in increased 
levels of antigen specific T-cells, and stimulates mature dendritic cells in efficient 
antigen presentation.  [4] Preclinical and clinical studies suggest the role of the 
TLR’s in modulating anti-tumor immunity. TLR-7 and TLR-8 are key targets of 
Aldara™ cream (imiquimod) for the treatment of basal cell carcinoma, actinic 
keratosis and genital warts. [5, 6] Aldara™ cream operates as an immune 
modulator in the MyD88 pathway resulting in a high antitumor and antiviral 
effect. [5] Imiquimod is contained in TMX-101, a new drug formulated for 
intravesical use with anti-proliferative effects against urothelial carcinoma as 
well as anti-tumor effects in preclinical research. [7] Falke et al. published part 
I of a multicentre phase I dose-escalation study, in which TMX-101 was given 
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after complete TURBT with six weekly instillations. This study showed that 
TMX-101 is safe, AE’s are common but mild and limited to the genitourinary 
tract, and the systemic uptake is low. [8] Subsequent the TMX-101 part II study 
was conducted to determine the activity on a marker-lesion and to analyze the 
Pharmacodynamic (PD) and Pharmacokinetic (PK) characteristics of TMX-101. 
The results of this study are presented in this manuscript, supplemented with 
additional validated safety data from parts I and II.
Materials and Methods
After institutional review board approval 7 patients were included in part II of 
this open label, multicenter, prospective phase 1 trial from June 11th 2010 until 
July 4th 2013 in accordance with The Declaration of Helsinki.
Patients selection
Patients with Ta-T1 low-grade histologically conformed urothelial carcinoma 
of the bladder were eligible. Furthermore, patients had to be ≥18 years old, 
have an Eastern-Cooperative-Oncology-Group-performance-score of 0 to 1, 
and have adequate renal, hepatic and hematological status. Ineligibility criteria 
were: previous or current high-grade urothelial carcinomas, current high-grade 
cytology, muscle-invasive bladder carcinoma, inability to retain an intravesical 
instillation for 1 hour, uncontrollable bladder infections, history of upper urinary 
tract disease, immune compromised patients, active malignancies other than 
urothelial carcinoma and basal cell carcinoma, previous or present radiotherapy/
brachytherapy, suspicion of hypersensitivity to the study drug, pregnant or 
breastfeeding women, participation in other studies with investigational drugs, 
intravesical chemotherapy within six months before study entry and intravesical 
inmmunotherapy within 24 months before study entry. Women of childbearing 
potential and sexually active men had to agree to use contraception.
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Treatment and study design
Prior to inclusion multiple (2-7) tumors had to be present. Patients underwent 
TURBT with one marker-lesion remaining, between 0.5cm and 1.0cm in diameter, 
documented by video or photo. Because the maximum tolerated dose (MTD) 
was not reached in part I of this trial [8], patients were enrolled in a sequential 
manner and treated with the two highest doses of TMX-101 administered in 
part I; 0.2% (100mg in 50ml) or 0.4% (200mg in 50ml). The drug was instilled 
once a week for six consecutive weeks, starting within three weeks after marker-
lesion TURBT. The drug was retained by the patient for one hour. No direct 
postoperative intravesical instillation was given after the TURBT. A cystoscopy 
was performed 2-4 weeks after the last instillation and, if necessary, a second 
TURBT was planned to eradicate the remaining marker-lesion. 
Patient evaluation
Primary objective was to detect the EBD (=CR in >2 patients) by determination 
of the post-treatment response, defined as CR, no response (NR), disease 
progression (DP), or not evaluable (NE). The second objective was to analyze PD 
and PK characteristics of TMX-101 and to determine TLR-7 expression in tissue 
samples by immunohistochemistry after initial TURBT.
Additional and validated safety data, determined by AE rates of all patients (part 
I and II), are described in Appendix A. The presence, severity and frequency of 
AE’s were assessed in the weeks of treatment, and defined according to Common 
Terminology Criteria of Adverse Events (CTCAE) 4.02. Vital signs, blood analysis 
(hematology, chemistry, immunoglobins) and urinalysis (culture, macroscopic, 
microscopic) were standard weekly monitoring procedures.
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Pharmacodynamics and pharmacokinetics
Urine samples, for PD- and PK-evaluation, were collected from all patients at 
screening, pre-dose and one hour after instillation. One patient in each dose 
group was asked to sign additional informed consent to collect extra blood 
samples at pre-dose, 0.5, 1.0, 1.5, 3.0, 4.5 and 6.0 hours, as well as urine samples 
from 1 to 3 hours and 3 to 6 hours after the first and last treatment session for 
PK-analyses.
Plasma samples were analyzed for concentrations of the study drug by liquid 
chromatography-mass spectroscopy with a detection range of 0.025 to 10 ng/
ml. Urine samples were analyzed for TMX-101 with a detection range of 5 to 
2500 µg/ml. All plasma and urine PK analyses were performed by a certified 
external laboratory (Quotient Bioresearch Ltd., Forham, United Kingdom). 
A Multi-Analyte Profile technology, based on Luminex technology, was used to 
simultaneously measure 32 urinary markers such as cytokines, chemokines, 
growth factors and matrix-metalloproteinases, since these markers may 
indicate a pro-inflammatory reaction. This analysis was conducted at EDI GmbH, 
(Reutlingen, Germany). [9]
Recruitment and statistical methods
Initially nine patients were planned to participate (three patients in 0.2% [100 
mg/50ml], and six patients in 0.4% [200 mg/50ml]). This was not based on 
statistical assumptions, rather the sample size of this study followed a well-
established current methodology (3+3 cohort design) of dose-finding studies (in 
part I) with additional subjects added at the MTD/EBD or maximum achievable 
dose (in part II). However, after inclusion of seven patients, the study was closed 
prematurely due to delayed recruitment, even after the initial recruitment 
period of two years was extended by one year. The difficult recruitment was 
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mainly due to previous intravesical chemo- or immunotherapy exposure, which 
resulted in exclusion. Furthermore, the marker-lesion concept was frequently 
an issue for potential patients. Three more centers were included during the 
recruitment period. Unfortunately, the same issues were encountered there, 
and patient inclusion remained low. The decision to early terminate the study 
was taken after three years, at the time instillations, cystoscopic evaluation and, 
if necessary, a second TURTB were completed in seven patients. All statistical 
analyses are descriptive.
Results
Among the 23 patients in part I&II, 21 patients (14 patients in part I (87.5%) and 7 
patients in part II (100.0%)) completed treatment. The mean age was 60.3 years. 
All patients of part II had recurrent NMIBC. Overall, the mean time since initial 
diagnosis was 6.3 years. All baseline characteristics are summarized in table 1.
Activity results
All patients in part II were evaluated 2-4 weeks after the last instillation. None of 
the patients achieved CR. An EBD of TMX-101 could not be defined because none 
of the patients had CR to the study treatment. No significant in- or decrease of 
the marker-lesion itself was observed, and the marker-lesion was eradicated by 
a second TURBT. Histology reports of the second TURBT were comparable to the 
initial TURBT in terms of stage and grade (5 times pTaG1 and 2 times pTaG2a).
Pharmacodynamics
Thirty-two urinary cytokines, chemokines, growth factors and matrix-
metalloproteinases were measured in urine samples one-hour post instillation. 
IL-1ra seems to represent the most sensitive and uniform biomarker of treatment 
observed in these urine samples. IL-1ra exhibited the highest concentrations 
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after TMX-101 instillations. Moreover, a pronounced increase after every 
treatment time point was clearly seen in 22 patients (figure 1). In one patient 
no urinary mediator response was seen, including IL-1ra. IL-1a, IL-6 IL-8, IL-18, 
MIP-1β, MCP-1, and VEGF also showed changes that could be related to the 
instillation. However, this was not observed uniformly. No dose-dependent 
difference in cytokine concentrations could be established in these analyses 
(data not shown).
N= 23 part I part II part I&II
Gender
  No. Male (%)
  No. Female (%)
11 (68.8)
5(31.2)
5 (71.4)
2 (28.6)
16 (69.6)
7 (30.4)
Mean age (SD) 57.3 (12.7) 67.4 (11.1) 60.3 (12.9)
  NMIBC
  Primary (%)
  Recurrent (%)
3 (18.8)
13 (81.2)
0 (0.0)
7 (100.0)
3 (13.0)
20 (87.0)
  Time to initial diagnosis; yrs 6 7 6.3
NMIBC stage at inclusion
  Ta (%)
  T1 (%)
15 (93.8)
1 (6.2)
7 (100.0)
0 (0.0)
22 (95.7)
1 (4.3)
NMIBC grade at inclusion
  Low-grade (%)
  High-grade (%)
16 (100.0)
0 (0.0) 
7 (100.0)
0 (0.0)
23 (100.0)
0 (0.0)
Dose level
  25 mg (%)
  50 mg (%)
  100 mg (%)
  200 mg (%)
4 (25.0)
4 (25.0)
4 (25.0)
4 (25.0)
0 (0.0)
0 (0.0)
3 (42.9)
4 (57.1)
4 (17.4)
4 (17.4)
7 (30.4)
8 (34.8)
Table 1. Baseline characteristics part I and part II.
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Pharmacokinetics
Six patients of part I (N=4) and II (N=2) were selected for PK-analysis after the 
first and sixth instillation. Time to maximum TMX-101 plasma concentration 
(Tmax) was between 0.5-1.5 hours from start of the instillation, independently 
of the dose and number of instillation (first or sixth). Maximum concentrations 
(Cmax) of TMX-101 seems independent to the dose increase, except for the 
Figure 2. Photomicrographs of TLR-7 (rabbit clone EPR2088(2)) immunohistochemistry 
staining in sample ID 1-7. Tumor: 1,5,7. Normal mucosa: 2-4,6.
Figure 1. Mean and 95%-CI of pre- and post-instillation concentration of pooled IL-1ra 
data in all patients (N=23). (253 evaluable urines out of 276 collections time points 
(91.7%)).
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Dose (mg) Instillation
Cmax
(ng/ml)
Tmax
(hours)
AUC  
(ng*hr/ml)
T1/2
(hours)
25* 1 (patient part I)*# 3.14 1.0 7.37 2.72
1 (patient part I)*
6 (patient part I)*
1.30
4.33
0.5
0.5
0.10
9.71
-
1.98
50* 1 (patient part I)*
6 (patient part I)*
1.64
7.62
1.5
1.0
4.76
15.97
1.86
2.47
100 1 (patient part I)*
6 (patient part I)*
1 (patient part II)
6 (patient part II)
1.74
2.23
17.7
5.78
0.5
0.5
1.0
1.0
5.14
4.54
28.77
13.18
-
-
1.24
1.77
200 1 (patient part I)*
6 (patient part I)*
1 (patient part II)
6 (patient part II)
59.0
71.7
75.1
8.75
1.5
1.0
1.0
1.5
170.00
157.43
132.53
26.87
1.99
-
-
2.44
* part I data 
# patient discontinued after instillation 2 and was replaced by another patient
Table 2. Pharmacokinetic data of TMX-101.
Table 3. TLR-7 immunohistochemistry (rabbit clone EPR2088(2)) Staining results.
Sample ID Tissue type % Positive / H-score
1 Bladder tumor 95%
2 Normal mucosa 75%
3 Normal mucosa 100%
4 Normal mucosa 50%
5 Bladder tumor 60%
6 Normal mucosa 75%
7 Bladder tumor 70%
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highest dose level (table 2). The area under the curve (AUC) value reflects the 
same independence to dose increase, except for the highest dose level (with 
an exception for instillation 6 in patient part II). The mean elimination half-
life (T1/2) is independent of the dose and instillation, 2.1 ± 0.5 hours. No drug 
accumulation occurred.
TLR-7 expression
Weak cytoplasmic expression of TLR-7 (rabbit clone EPR2088(2)) was observed 
in normal epithelia or cancer cells for all samples, ranging from 50% to 100% with 
an average of 75%. Moderate to strong cytoplasmic staining was also observed 
in inflammatory cells. Expression of TLR-7 was compared between 3 tumor 
samples and 4 normal samples and the results were similar. Average expression 
in both groups was 75% (Table 3).
All samples were also evaluated by image analysis. TLR-7 expression was 
observed in all samples, ranging from 9% to 43% with an average of 19%. No 
differences between normal epithelia and cancer cells were observed. Lower 
average expression was observed by image analysis due to the entire tumor 
tissue, including a variety of normal cells, was included (Figure 2).
Discussion
TMX-101 is a novel formulation of imiquimod optimized for the intravesical 
treatment of NMIBC. Imiquimod is a targeted small molecule, a compound of the 
imidazoquinoline family (TLR-7 agonists), and causes potent anti-viral and anti-
tumor immune responses. [8] In previous preclinical research, TMX-101 showed 
an anti-proliferative effect against urothelial carcinoma as well as an anti-tumor 
effect. [7] In part I the safety was demonstrated of six instillations with TMX-101 
in 16 patients after complete TURBT. [8] In part II the recruitment was terminated 
early, due to previous mentioned difficulties, after seven patients underwent a 
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marker-lesion TURBT, followed by six consecutive weekly instillations of TMX-
101 to determine the EBD, to analyze the PD and PK characteristics, and further 
examine its safety. The EBD, defined as CR in more than two patients, could not 
be determined as no CR was experienced.
Immunotherapy in NMIBC is the standard intravesical treatment for decades. 
Instillation of BCG results in local immune response due to maturation of dendritic 
cells (DC) and secretion of cytokines, which leads to tumor specific cell death. 
Unfortunately, relapses in BCG-therapy are common and serious systemic side-
effects do occur. Research into safer and more effective intravesical treatments 
is needed. TMX-101 has a similar proinflammatory cytokine response in-vitro 
as BCG [10], and could therefore be effective in NMIBC. Smith et al. performed 
an in-vitro and in-vivo study in which this anti-tumor effect was demonstrated. 
[7] Hayashi et al. showed that the tumor load in mice treated with imiquimod 
was significantly lower compared to vehicle-treated or non-treated mice. [11] 
However, these in-vivo anti-tumor effects were observed in models with high-
grade urothelial carcinoma. Due to the marker-lesion design only low-grade 
NMIBC were allowed to participate, unfortunately without any activity effects. 
The discrepancy between preclinically and clinically selected tumors could be of 
influence on the activity results in this study. Furthermore, it could be possible 
that a positive effect on a marker lesion was missed due to the low number 
of patients, the schedule, the time period for assessment (2-4 weeks), or that 
additional cycles are needed to observe an antitumor effect. To clarify these 
above mentioned ambiguities, further studies are needed.
Regarding the PD-results, IL-1ra seems to be the most constantly induced 
mediator stimulated by TMX-101 in all patients. Except for one patient, all post-
instillation time points showed a pronounced increase of this cytokine. Moreover, 
IL-1ra reached the highest concentrations in comparison to other mediators. The 
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IL-1 family plays an important role in inflammatory and immunologic processes, 
and according to Dinarello et al. the inhibition of IL-1, the major role of IL-1ra 
during immune responses, can reduce tumor burden and tendency of tumors to 
metastasize. [12] Several other studies support the evidence of IL-1 dependent 
angiogenesis in malignancies. [13-15] Furthermore, injection of IL-1ra reduced 
tumor-colonies by 50% and -volume by 70% in hepatic metastasis models. [16] 
Due to the increased IL-1ra concentrations one could assume an inflammatory 
response resulting in IL-1 inhibition. Nonetheless, no response was seen on 
the marker-lesion. This could be due to the treatment schedule limited to six 
instillations not followed by maintenance, the dose, or the relatively short 
follow-up. However, the IL-1ra response to TMX-101 exposure could be valuable 
for future biomarker purposes in individualized therapy. 
The anti-tumor involvement for IL-6, IL-8, IL-18, MCP-1, and VEGF have been 
described in BCG immune responses. [9, 17-19] Nevertheless, the cytokine 
peaks in this study were too variable to draw any conclusions. 
PK-analyses show detection of imiquimod in plasma of all PK-patients after TMX-
101 instillation, whereas the pre-dose plasma levels were below detection limits. 
Consequently, no drug accumulation was observed. The imiquimod mean Cmax 
and AUC is under proportional to the dose increase except for the highest dose 
(200 mg), where the mean Cmax and AUC show a remarkable over proportional 
increase. It appears that there is a threshold level of absorption. One could 
speculate that this is the result of increase in the rate of passive drug diffusion 
through the bladder wall for the 200mg dose group. The C-max results of the 
200mg doses support this hypothesis, with an exception for the result of the sixth 
instillation in the last included PK-patient (Cmax: 8.75ng/ml), which is difficult to 
explain in this small amount of PK-patients. Despite the higher systemic uptake in 
the 200mg dose group, the plasma values are still below the oral intake (100mg) 
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or subcutaneous administration (30mg) of imiquimod, that was not associated 
with toxicities (123 and 128 ng/ml, respectively). [8, 20, 21] The PK-data in this 
cohort is limited due to ethical considerations: blood sampling for six hours after 
the instillation was allowed in one patient per dose group.
TLR-7 is expressed at the endosomal membrane of monocytes, macrophages, 
plasmacytoid-DC’s and mast-cells [22, 23] DC’s not only exhibit the unique 
capacity to evoke primary immune responses, but also may acquire TLR-triggered 
cytotoxic activity. [24] 
Strong TLR-7 expression on immune cells was observed in tumor and normal 
bladder tissue, a weak staining of epithelial cells was also observed, with 
a comparable expression between normal and tumor tissue. Hemmi et al. 
demonstrated that activation of TLR-7 by imiquimod leads to an intracellular 
signaling cascade causing anti-viral and anti-tumor immune responses. [25] 
Despite the presence of TLR-7 in all examined bladder tissue, no significant effect 
was seen on the marker-lesion in any of the patients. Nonetheless, TMX-101 
could still be effective in other doses, schedules or formulation. Furthermore, 
the type of NMIBC could be of influence to the effect of TMX-101, and high-
grade patients might well benefit more as was suggested by preclinical work. [7, 
11] Further research with TMX-101 has been established in a phase II pilot study 
with CIS patients giving promising preliminary results. Definitive results of this 
study are expected shortly. (www.clinicaltrials.gov;NCT0173165)
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Conclusions
TLR-7 agonists have been effective in urothelial carcinoma in preclinical 
research. In this phase I study TMX-101 has shown to be safe regarding its 
systemic uptake and side-effects in a total of 23 patients. The EBD could not be 
determined, because no effect was observed on the marker-lesion in a limited 
number of patients (N=7). IL-1ra could be a valuable urinary biomarker in future 
developments. A phase II pilot study in CIS patients is currently ongoing and 
results are expected shortly.
Clinical practice points
There is an unmet need for new, effective and safe intravesical therapies in non-
muscle invasive bladder cancer (NMIBC) patients to lower recurrence rates. 
TMX-101 is the new liquid form of imiquimod, a toll like receptor 7 agonist, 
for intravesical instillation and is effective in-vitro against urothelial NMIBC. In 
this study seven patients underwent a marker-lesion transurethral resection of 
the bladder tumor (TURBT) and six weekly instillations with TMX-101 0.2% or 
0.4% to determine the effective biological dose (EBD, = complete response in 
>2 patients). Unfortunately, no EBD could be defined as none of the subjects 
achieved a complete response. Despite the negative findings in this study, these 
results can contribute in the development of new effective intravesical therapies 
and guide and inform other research groups. The effect of TMX-101 is currently 
evaluated in CIS-patients and results are expected shortly. 
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Appendix A
Safety results
Safety of TMX-101 was assessed for patients enrolled in part II, supplemented 
with validated data of part I of the study. Overall, 87% of patients (15 patients 
in part I and 5 patients in part II) reported at least one Treatment-Emergent 
Adverse Event (TEAE). All events were of CTCAE ≤ Grade 2 intensity (table 
1). Most frequently reported TEAEs were urgency (34.8%), fatigue (21.7%), 
bladder discomfort and bladder pain (17.4%, in both). TEAEs leading to study 
discontinuation were reported for 2 subjects in part I. [1] No treatment was 
required and all side effects resolved without sequelae. There were no serious 
TEAE reported. Clinical significant changes in laboratory parameters and/or vital 
signs were not observed, during or after treatment exposure. The Maximum 
Tolerated Dose (MTD) of TMX-101 was not reached. Dose Limiting Toxicities 
(DLT) were not reported.
Table 1. Number of drug related adverse events per CTCAE grade and dose group
Dose group (mg) Grade I Grade II Totals
  25 (part I; N=4) 10 12 22
  50 (part I; N=4) 11 11 22
  100 (part I; N=4) 11 12 23
  200 (part I; N=4) 15 4 19
TOTAL PART I 47 39 86
  100 (part II; N=3) 12 0 12
  200 (part II; N=4) 6 0 6
TOTAL PART II 18 0 18
TOTAL PART I&II 65 39 104
Note: observed differences with Falke et al. [1] are the result of data cleaning.
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Discussion
In part I and II no DLT were reported. The MTD was not reached and none of the 
subjects endured a serious TEAE. Two of the 23 included patients dropped out of 
the study (part I), both after instillation two, due to mild/moderate complaints. 
One of these two patients (treated with 50mg TMX-101) reported bladder pain 
and a burning irritating sensation of the glans penis, obviously related to the use 
of the study drug. The second patient (treated with 25mg TMX-101) reported a 
burning sensation of the skin of both legs, which was considered as unrelated to 
the study drug. No intervention was required to resolve these complaints. In total 
104 drug related adverse events were reported in all subjects, in which the vast 
majority was urgency/frequency. Numbers in this series are too low to compare 
these side effects with the common side effects of other intravesical (immuno)
therapies. In view of the results of part I and II of this study the conclusion may 
be drawn that TMX-101 has an acceptable safety profile in patients with NMIBC 
after six consecutive weeks of instillation. 
1. Falke J, Lammers RJ, Arentsen HC, Ravic M, Pozzi R, Cornel EB, et al. Results of a 
phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle 
invasive bladder cancer. The Journal of urology. 2013;189:2077-82.
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Although the awareness of bladder cancer (BC) is low in the general population, 
the impact on our healthcare infrastructure and costs is higher than initially 
expected. Considering incidence, BC is the sixth most common cancer (and it is 
even fourth most common if stage Ta is included). [1] Worldwide approximately 
2.7 million patients have been diagnosed, treated and/or followed-up for BC 
at any given time point and, per patient, BC is the most expensive cancer. [2-
4] Although transurethral resection of the bladder tumour (TURBT) is the gold 
standard treatment in BC, residual or recurrent disease within three months 
after TURBT for non-muscle invasive BC (NMIBC) can be up to 45%. [5-8] 
For NMIBC, residual and early recurrent BC after TURBT is mainly the result of 
detection difficulties with a normal white-light cystoscope, which is reflected 
in a low sensitivity. New techniques as fluorescence cystoscopy during TURBT 
improves accuracy by using photo sensitizers. Especially detection rates of 
carcinoma-in-situ (CIS) improve with the help of fluorescence cystoscopy, as this 
type of BC can be easily missed with normal white-light cystoscopy because of 
its flat appearance. Narrow-Band-Imaging (NBI) uses the benefit of wavelength 
differences between normal urothelium and hypervascular BC-tissue. By filtering 
white light into two bandwidths this technique can better identify vessels which 
offers a higher sensitivity for detecting small papillary tumours and CIS, without 
any preoperative bladder instillation.  These relatively new imaging techniques 
provide better tumour detection during TURBT and a more complete tumour 
resection; which leads to lower recurrence rates. Nonetheless, one should 
realize the small increase in false-positive biopsies associated with these new 
techniques.
Beside new cystoscopy techniques, adjuvant intravesical treatment after TURBT 
remains crucial to decrease the recurrence rate of BC. [9] In low-risk non-muscle 
invasive BC (NMIBC), a direct single postoperative instillation of chemotherapy 
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is recommended and sufficient. In intermediate-risk NMIBC, one year of 
intravesical treatment with either chemotherapy or Bacillus Calmette-Guérin 
(BCG) is recommended. In high-risk disease, BCG induction, followed by at least 
one year of full dose maintenance therapy is advised; three years maintenance, 
as well as adjustment of the dose, might be considered. [9] To date, however, 
compliance with the guidelines is low, resulting in more tumour recurrence and 
sometimes even tumour progression. This low compliance is probably due to the 
toxicities of intravesical therapies, who cannot be underestimated. The search 
for new, more effective, and safer therapeutic NMIBC options is continuously 
developing. This theses emphasizes the need for new treatment options and 
mainly focuses on the additional value of chemohyperthermia (CHT) in NMIBC-
patients. In the last chapter of this thesis a more experimental immunotherapy 
against NMIBC has been described.
New intravesical treatments for NMIBC
As described in this thesis, CHT could be an equivalent alternative therapy in 
comparison with BCG instillations. For decades BCG therapy achieved the best 
results in terms of recurrence free survival for intermediate- and high-risk NMIBC. 
Despite extensive research into other conservative therapies, BCG remained 
the therapy of choice. Besides the relatively good therapeutic outcome, BCG 
instillations has potentially serious systemic side-effects. 
Recently, there has been a worldwide shortage of BCG, resulting in a tremendous 
adjuvant treatment dilemma for intermediate- and high-risk NMIBC patients. 
These shortages emphasize the fact that alternatives for BCG have to be 
investigated and brought into clinical practice on a short notice. With the results 
of the 102-study (chapter 3), future shortages could be (partly) countered with 
adjuvant CHT treatment. The 102-study is the first hyperthermia manuscript 
that provides randomized prospective data that compares CHT with BCG. The 
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recurrence free survival results were in favour of CHT therapy, but the study 
was slightly underpowered. Therefore, it would be convincing if a second 
randomized trial confirmed these results. A few aspects could been optimized in 
a future trial. For example, although the duration and frequency of maintenance 
therapy is still unknown, ongoing experience in the last ten years has learned 
that better results can be achieved with longer maintenance therapy. [10] In 
light of this experience a second CHT versus BCG trial could implement a longer 
maintenance period, for instance, three years instead of one. In addition to the 
prolonged maintenance period, the 102-study seems to be negatively influenced 
by patients that had a bladder capacity at the lower end of the inclusion criteria 
(150-200mL). Ongoing experience learned us that a bladder capacity of ≥200cc 
results in higher recurrence free survival rates, since side-effects are less common 
in these patients. Therefore, inclusion criteria regarding the bladder capacity in 
new trials should be upgraded to at least 200cc. Preparations of such a trial are 
currently in progress and recruitment of patients is expected in the first quarter 
of 2016 (Clinicaltrials.gov Identifier: NCT02254915). Besides the promising 
results of CHT, it would be influential when the exact mechanism of action is 
understood. Several hypotheses exist on this matter, without convincing scientific 
evidence to support them. These hypotheses range from higher permeability of 
the bladder wall, to higher cytotoxic effects by causing cell cycle arrest, to higher 
effectiveness of MMC itself due to the higher temperature. [11-13] None of 
these hypotheses, however, have been indisputably proven and more research 
in this area is needed to fully understand the mode of action in CHT.
Another relatively new intravesical therapy that induces the efficacy of 
Mitomycin-C (MMC) is intravesical electro motive drug administration (EMDA). 
EMDA increases drug uptake in the urinary bladder, by creating an electrical 
gradient between the intravesical chemotherapeutic agent and the bladder 
wall, resulting in improved clinical efficacy in NMIBC. [14, 15] Intravesical BCG, 
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followed by EMDA with MMC in patients with high-risk NMIBC, leads to higher 
disease-free intervals, lower recurrence and progression rates, and improved 
overall survival and disease-specific survival rates, compared with BCG alone, 
according to Di Stasi et al. [16] The underlying idea is to increase the permeability 
of the bladder mucosa by BCG-induced inflammation, allowing MMC to reach 
the target tissue more easily and exert its anticancer effect. There tended to 
be more side effects in the EMDA-MMC group than with passive MMC, but 
still significantly fewer than with BCG. This sequential schedule might also be 
interesting for investigation with other intravesical drugs; e.g. CHT and BCG.
A recent publication of the same group reported on a multicenter, randomized, 
parallel-group study in patients with primary non-muscle invasive BC. Patients 
were treated either with TURBT alone (n=124), or TURBT with an immediate post-
operative MMC passive diffusion bladder irrigation (n=126), or pre-operative 
EMDA-MMC (n=124). The results showed, that intravesical EMDA-MMC before 
TURBT is feasible and safe. It reduces recurrence rates and seems to enhance the 
disease-free interval compared with TURBT alone or with intravesical passive 
diffusion of MMC after TURBT in intermediate- and high-risk patients. [17] The 
authors hypothesize that high MMC concentrations in bladder tissue can destroy 
or inhibit the implantation of viable cancer cells that could have been released 
during TURBT and thus reduces the recurrence rate of NMIBC.
Although, EMDA seems promising as a neoadjuvant treatment to improve 
TURBT outcome, it has never been reproduced by another centre. It is necessary 
to externally validate its findings in more phase II/III trials with sufficient follow-
up. While, EMDA could take a prominent place in the pre-TURBT setting, there 
is still need for effective and save adjuvant instillations after TURBT to lower the 
amount of recurrences. 
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The above described concept of neoadjuvant chemotherapy is widely 
implemented in oncological care, including muscle-invasive bladder cancer. In 
NMIBC, however, neoadjuvant intravesical chemotherapy is not (yet) part of the 
standard clinical approach. Besides the study from Di Stasi et al. in 2011, only 
a few other research groups presented data among this subject. [18, 19] The 
most interesting results in this subject are from the phase II study by Colombo 
et al. [18] In this study 54 recurrent low-risk NMIBC patients were divided in two 
groups: group one received six weekly neoadjuvant MMC instillations, group 
two received six neoadjuvant MMC instillations in two weeks. TURBT within two 
weeks after completing the treatment showed a 44% complete response (CR) 
rate in group one versus a CR of 70% in group two (p=0.04). If these results are 
validated in larger cohorts, with long-term results, TURBT could be avoided in 
more than 50% of all low-risk NMIBC patients.
Regarding TMX-101, it is a setback for this potential new immunotherapeutic 
agent that the first phase I trial had a negative result for the included NMIBC 
patients (chapter 5). TMX-101 has a similar pro-inflammatory cytokine response 
in-vitro as BCG [20], and could therefore be effective in NMIBC. Smith et al. 
performed an in-vitro and in-vivo study in which this anti-tumour effect was 
demonstrated. [21] Hayashi et al. showed that the tumour load in mice treated 
with imiquimod was significantly lower compared to vehicle-treated or non-
treated mice. [22] However, these in-vivo anti-tumour effects were observed in 
models with high-grade urothelial carcinoma. Due to the marker-lesion design 
only low-grade NMIBC were allowed to participate, unfortunately without any 
activity effects. The discrepancy between pre-clinically and clinically selected 
tumours could be of influence on the activity results in this study. Furthermore, 
it could be possible that a positive effect on a marker lesion was missed due 
to the low number of patients, the schedule, the time period for assessment 
(2-4 weeks), or that additional cycles are needed to observe an antitumor effect. 
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To clarify these above mentioned ambiguities, further studies are needed.  A 
pilot study with TMX-101 in CIS patients has been established giving promising 
preliminary results. Definitive results of this study are expected shortly 
(Clinicaltrials.gov; NCT0173165).
One of the newest development in bladder instillations, that may bypass the 
drawbacks of the current instillation mode, is the TC-3 gel. To date, no publication 
on this subject does exist. Intravesical MMC using TC-3 gel is expected to 
increase treatment efficiency due to prolongation of treatment duration and 
consequently improving bladder exposure to MMC. The technology is based on 
a reverse thermal (low viscosity at 5°C) degradable gel (TC-3) for MMC retention 
in the urinary bladder. Prior to instillation, the cold TC-3 gel (in a liquid state) 
is mixed with MMC. Following gel insertion into the bladder by catheter, the 
gel rapidly solidifies at body temperature and forms a drug reservoir inside the 
bladder. Upon contact with urine the gel dissolves, MMC is released gradually 
and leaves the bladder upon voiding.
Recently, an open label study has been completed, evaluating short term safety 
and tolerability of TC-3 gel for retention of MMC in the urinary bladder in patients 
with muscle invasive bladder cancer prior to radical cystectomy (Clinicaltrials.
gov ID: NCT01648010). Results are awaited. Another study, comparing TC-3 gel 
MMC treatment (with sustained release mechanism on the drug) in low risk 
recurrent NMIBC patients, to standard treatment with MMC bladder instillations, 
is now recruiting patients (Clinicaltrials.gov ID: NCT01803295). Results are to be 
expected in 2017.
New intravesical treatments after BCG
To date, most patients with recurrence or relapse after BCG can be offered a 
second course. [9] In case of definitive BCG failure, the AUA and EAU treatment 
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guidelines recommend the consideration of cystectomy in patients with high-
grade recurrences. [9, 23] Early cystectomy in BCG failure patients is associated 
with good recurrence free survival rates, up to 90% after five years. Additionally, 
BCG failures, with tumour progression to muscle-invasive BC, have a tremendous 
survival drop in comparison to primary muscle-invasive BC patients. [24-26] On 
the other hand, some of the BCG failure patients with early cystectomy will be 
over treated, and become disadvantaged by the co morbidity, mortality and 
impaired quality of life associated with this major surgery. 
Currently there are no clinical decision tools available to distinguish the patients 
with high-risk, from those with low-risk, on tumour progression. However, with 
clinical and histological parameters, risk groups can and should be identified. 
Gender, concomitant CIS, methylation status of tumour tissue, depth of invasion 
(pT1 sub-staging) and a combination of urinary markers (with emphasis on 
urinary IL-2) might be helpful tools to predict the chance (and outcome) of 
BCG failure. [27-29] These prognostic factors could be used in the challenge of 
deciding who will be a candidate for adjuvant intravesical treatment and who 
will benefit most from early cystectomy. 
Despite extensive research there is a lack of good alternative conservative 
treatment options after BCG failure. Gemcitabine seems to be superior in BCG 
refractory patients as compared to more BCG, although data are still limited and 
more research is needed. [30] Valrubicin, another chemotherapeutic agent, is 
specifically indicated and FDA approved for use in patients with BCG-refractory 
CIS. An earlier study reported a CR rate of 42%. [31] A recent trial, however, 
could not confirm this and showed a CR rate of only 18%. [32]
In conclusion, BCG failure in high risk NMIBC patients is of great importance, 
since those patients are at risk of progression to muscle invasive disease, which 
is associated with a poor outcome. Radical cystectomy remains the mainstay for 
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this type of BCG failure patients. With appropriate selection, certain patients 
who failed BCG (but without unfavourable risk factors) can be treated with 
additional conservative intravesical options. The difficulty lies in deciding who 
to select for early radical cystectomy and who will benefit from conservative 
treatment, since the outcome after progression is far worse.
Urinary biomarkers in NMIBC
In the last decade there has been extensive research to the value of molecular 
markers. Since follow-up of NMIBC is still inevitable because of its high recurrence, 
there is a big need for a simple, non-invasive and cheap diagnostic test. A highly 
sensitive and specific marker to detect BC could decrease morbidity and costs 
associated with cystoscopy. [33] Although various reviews of molecular urinary 
markers have appeared, none of them are currently used as a standard diagnostic 
or follow-up procedure in routine urology, nor are they routinely advised in 
guidelines. [33, 34] Six of these markers are already commercially available, 
but the high molecular diversity of urothelial BC results in limited sensitivity 
and specificity. Moreover, high costs and the need for expert analysis do not 
contribute to their implementation. Due to the limited sensitivity and specificity, 
researchers nowadays try to combine several single urinary markers to increase 
the reliability and create a non-invasive test that is ready for integration into 
clinical decision making. [35, 36] Even though the utility of molecular markers 
in BC remains of limited use and further research is necessary, its additional 
benefits in the near future could be very promising.
In this theses we described a set of biomarkers for CHT with a possible predictive 
urinary biomarker for the CHT outcome. Clearly, a reliable predictive urinary 
biomarker for CHT would be of great value because early termination of CHT 
treatment in non-responding patients could be realized, saving unwanted drug 
expense and loss of quality of life, without pathologic or cystoscopic confirmation. 
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In this pilot study MDC levels after the first week of treatment were significantly 
higher in the CHT responders compared to the non-responders (chapter 5). 
Whether these observed differences in MDC peak levels can reliably predict 
direct CHT outcome needs further study, since the number of patients studied 
are very limited. For example, no statement about the duration of response, for 
those patients with high MDC peak levels, is possible due to the limited patient 
number. Based on the results of this first study a multicenter study should and 
will be initiated to validate these first outcomes. In this next study, we aim to 
validate the observed urinary cytokine level differences between cold and warm 
MMC therapy and try to confirm that MDC levels correlate with a favourable 
clinical outcome in CHT patients. In contrary to the pilot study, follow-up data 
will be collected to determine the duration of CHT effect and last but not least, 
the inclusion criteria will be adjusted to realize a more homogeneous study 
group regarding stage, grade, recurrence, gender and age.
Regarding the heterogeneous aspects of NMIBC in general, urinary biomarkers 
could contribute in the selection of the adequate patient for different 
conservative therapies. In addition to urinary biomarkers, genetic profiling could 
also result in more accurate patient selection. In a retrospective designed study, 
the methylation status of tumour suppressor genes MSH6 and THBS1 predicted 
tumour progression in high-risk NMIBC patients undergoing BCG treatment. 
[27]. These recent developments in biomarkers and genetic profiling could help 
in personalising treatment options in this very heterogeneous disease. 
Hopefully, all the above mentioned steps contribute to safer therapies with lower 
recurrence and progression rates. And upfront cystectomy in NMIBC patients 
becomes unnecessary. 
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Bladder cancer (BC) is the most common malignancy of the urinary tract, due to 
its high incidence and very high prevalence caused by the relapsing nature of this 
disease. Therefore, BC has a tremendous effect on our health care infrastructure 
(Chapter 1). About 75% of patients with BC present with non-muscle invasive 
BC (NMIBC). Transurethral resection of the bladder tumour (TURBT) is the gold 
standard treatment in BC, followed by additional intravesical chemotherapy or 
immunotherapy. The choice for this additional intravesical treatment depends 
on the risk group of the NMIBC-patient. These risk groups are based on stage, 
grade, CIS, earlier recurrences, number of tumours and tumour size. The 
European NMIBC guideline formulates a comprehensible additional treatment 
advice for each of the three risk groups. However, compliance to the NMIBC 
guideline regarding additional intravesical instillations is low, which results 
in higher recurrence rates than necessary. Even with the correct application 
of additional instillations, however, recurrences in NMIBC are still relatively 
high. Moreover, the local and systemic toxicities of these instillations cannot 
be underestimated. New effective and safe intravesical treatment options are 
therefore highly needed.
Chemohyperthermia (CHT) is a relatively new intravesical therapeutic option for 
NMIBC. CHT is a computer-embedded intravesical irrigation system combined 
with an energy-delivering unit. The irrigation system consists of a disposable 
catheter system that delivers radiofrequency energy through an antenna . 
This system employs hyperthermia of the bladder wall induced by emission of 
radiofrequency energy, monitored by deployable thermocouples, combined 
with intravesical chemotherapy. In Chapter 2 patient and tumour characteristics 
of 160 patients treated with CHT were collected to evaluate the single centre 
recurrence-free survival (RFS). The vast majority of this cohort (96.3%) had non-
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responding recurrent NMIBC. Twenty (13%) patients were treated with CHT in 
combination with epirubicin, due to allergy for Mitomycin-C (MMC). The overall 1 
and 2 years RFS was 60% and 47%, respectively. In 4% muscle invasive progression 
was seen. The epirubicin subgroup showed a higher 2 years RFS in comparison to 
the MMC subgroup, however no significant difference was achieved. In another 
sub analysis the highly recurrent NMIBC group (≥3 recurrences/24months) had 
a significant decreased RFS, compared to the rest of the cohort. On multivariable 
analysis the highly recurrent NMIBC criteria remained independently associated 
with a decreased RFS. In conclusion, CHT seems to be an effective approach for 
NMIBC patients in which standard intravesical treatments fails. In addition we 
need to emphasize that these data do not yet show that hyperthermia is the 
treatment of choice after BCG-failure. The gold standard after BCG-failure still 
is radical cystectomy. Nonetheless, CHT can certainly be considered in selected 
cases.
Although the use of CHT as an alternative treatment is expanding in Europe, to 
date, there is a lack of prospective randomised data to compare CHT with BCG 
therapy. In Chapter 3 a randomized, controlled, open-label, multicentre trial is 
described in which the results of 1 year treatment with CHT is compared with 
the effect of 1 year BCG. RFS after 24 months in both groups was the primary 
objective in this study. In the intention-to-treat analysis, in which all patients 
with ≥1 treatment were analyzed, the 24 months RFS was 78.1% in the CHT 
group and 64.8% in the BCG group (p-value of 0.08). In the per-protocol analysis, 
in which all patients with ≥6 treatments were analyzed, the 24 months RFS was 
81.8% in the CHT group and 64.8% in the BCG group, with a p-value of 0.02. 
The per-protocol analysis resulted in better CHT results due to the fact that 10 
patients dropped out of the initial CHT group because of personal, medical and 
insurance issues. Progression to muscle-invasive disease was seen in <2% of 
both groups. The proportion of complete response (CR) at three months in CIS 
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patients, the second objective in this trial, was 88.9% in the CHT group and 85,7% 
in the BCG group, without any significant difference. No new safety concerns 
were identified for both intravesical treatments: BCG caused more systemic side 
effects like fever and malaise, while CHT caused more local bladder symptoms .
Despite the fact that the benefits of CHT have been confirmed by several 
(retrospective) studies, the exact mode of action is still poorly understood. 
CHT response is not uniform among different NMIBC-patients, however we are 
not able to distinguish responders from non-responders before treatment. In 
Chapter 4 an explorative study was conducted to identify changes in urinary 
cytokine/chemokine levels. Urinary cytokine/chemokine levels were collected 
longitudinally after CHT, and compared with levels of the same cytokines/
chemokines in patients receiving cold-MMC instillations. The primary objective 
of this pilot study was to examine whether urinary levels of selected CK’s 
differed between CHT treated and cold-MMC treated patients. The second 
objective was to evaluate whether CHT responders could be distinguished 
from CHT non-responders based on their cytokine profile. Elevated urinary 
CK levels were observed in both groups after treatment. In general, CK-peaks 
were lower in the cold-MMC group in comparison with levels in the CHT group. 
Significant higher MCP-1 and IL-6 levels were observed in CHT treated patients. 
MDC levels after the first week of treatment were significantly higher in the CHT 
responders compared to the non-responders. This first week MDC elevation in 
CHT responders could be valuable to personalize treatment. This could lead to 
early termination of treatment in non-responding patients, saving unwanted 
drug expense and unnecessary side effects. Whether the observed difference 
in MDC peak levels can reliably predict direct CHT outcome needs further study 
because the number of patients studied is very limited.
In Chapter 5 the efficacy of the new intravesical agent TMX-101 is discussed in a 
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multicentre, prospective phase I trial. TMX-101 is a part of the Toll like receptor 
(TLR) family, a conserved group of cell membrane proteins with a critical role in 
antimicrobial immunity and the proteins are a key component of the immune 
system. Preclinical and clinical studies suggest the role of the TLR’s in modulating 
anti-tumour immunity. TLR-7 and TLR-8 are also key targets of Aldara™ cream 
(imiquimod) for the treatment of basal cell carcinoma, actinic keratosis and 
genital warts. Imiquimod is contained in TMX-101. The ablative effect of TMX-
101 in a marker lesion setting was the primary objective of this trial. Despite the 
therapeutic effect of TMX-101 in urothelial carcinoma in a preclinical setting, no 
CR of the marker lesion in any of the participating patients was observed. Hence, 
the effective biological dose could not be defined. The safety of TMX-101 could 
been reconfirmed. New doses, other schedules and NMIBC-subgroups, should 
be tested to define the EBD of TMX-101. A pilot study in CIS-patients is currently 
ongoing and results are expected shortly.
Finally, in Chapter 6 the previous chapters of this thesis are discussed in a broader 
perspective and future developments in this field are highlighted. A summary of 
this thesis, in English and Dutch, is presented in Chapter 7.
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Blaaskanker is de meest voorkomende tumor van alle tumorsoorten in de 
urinewegen. Door de hoge recidiefkans van blaaskanker is frequente controle 
middels cystoscopie, cytologie en histologie niet te vermijden. Mede hierdoor 
heeft blaaskanker een groot effect op de gezondheidszorg en –kosten (Hoofdstuk 
1). Ongeveer 75% van alle initieel gediagnosticeerde blaaskankerpatiënten 
presenteren zich met niet-spierinvasieve blaaskanker. De behandeling van 
niet-spierinvasieve blaaskanker begint met een volledige transurethrale 
resectie van de blaastumor(en), gevolgd door intravesicale chemotherapie of 
immunotherapie. De adjuvante blaasspoeling met chemo-/immunotherapie is 
afhankelijk van de risicogroep waarin een patiënt zich bevindt. De risicogroep 
wordt bepaald op basis van het tumorstadium, tumorgradering, eerdere 
recidieven, aantal tumoren en tumorgrootte. Voor elk van de drie risicogroepen 
is er een duidelijk geformuleerde Europese richtlijn die de optimale adjuvante 
behandeling beschrijft. Echter worden deze behandelingsadviezen maar ten 
dele opgevolgd, wat resulteert in een hoger aantal recidieven dan noodzakelijk. 
Daarbij zijn de recidiefkansen in blaaskankerpatiënten, ook bij optimaal 
toegepaste adjuvante intravesicale behandeling, relatief hoog in vergelijking met 
andere tumorsoorten. En valt de toxiciteit van de intravesicale spoelingen niet 
te onderschatten, resulterend in ernstige lokale en systemische bijwerkingen. 
Effectievere intravesicale spoelingen met minder bijwerkingen zijn op basis 
van bovenstaande hard nodig. Dit proefschrift richt zich op nieuwe potentiële 
alternatieve intravesicale spoelingen.
Chemohyperthermie is een relatief nieuwe vorm van intravesicale instillatie. 
Bij deze vorm van adjuvante behandeling wordt de blaaswand verwarmd tot 
42 graden Celsius met behulp van een daarvoor speciaal ontworpen katheter, 
met een ingebouwde micromagnetron. Door middel van magnetrongolven 
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wordt de blaaswand verwarmd en tegelijkertijd mitomycine-C gespoeld over 
deze katheter. In Hoofdstuk 2 worden de 10-jaars resultaten beschreven van 
een monocentrische studie met 160 niet-spierinvasieve blaaskanker patiënten, 
waarvan het overgrote merendeel (96.3%) niet reageerde op conventionele 
spoelingen. Dertien procent van de patiënten werd gespoeld met epirubicine 
in verband met een allergie voor mitomycine-C. De resultaten van deze studie 
lieten een 1-jaars recidiefvrije overleving zien van 60% en een 2-jaars recidiefvrije 
overleving van 47%. Progressie naar spierinvasieve blaaskanker werd gezien in 
4% van de patiënten. Er was een hogere recidiefvrije overleving na twee jaar in 
de epirubicine groep, echter werd er in deze analyse geen significant verschil 
bereikt. In een subanalyse, waarbij hoogfrequent recidiverende blaastumoren 
(≥3 recidieven/24 maanden) werden vergeleken met de rest van het cohort, 
zagen we een significant lagere recidiefvrije overleving in deze subgroep. Ook 
bij multivariabele analyse was er voor deze groep een onafhankelijke associatie 
te zien met een lagere recidiefvrije overlevingskans. Concluderend lijkt op 
basis van deze studie chemohyperthermie een effectieve therapie voor niet-
spierinvasieve blaaskankerpatiënten waarbij conventionele spoelingen niet het 
gewenste effect hebben. 
Meerdere retrospectieve series zijn reeds gepubliceerd over de effecten 
van chemohyperthermie, echter zijn er geen prospectieve gerandomiseerde 
studies die het effect van chemohyperthermie vergelijken met BCG-therapie. 
In Hoofdstuk 3 beschrijven we de resultaten van een gerandomiseerde 
multicentrische studie waarin het effect van 1-jaars chemohyperthermie wordt 
afgezet tegen het effect van 1-jaars BCG-therapie. De primaire uitkomstmaat 
was de 2-jaars recidiefvrije overleving in beide groepen. In de Intention-To-Treat 
analyse, waarin alle patiënten werden geanalyseerd met ≥1 behandeling, werd 
een 2-jaars recidiefvrije overleving gezien van 78.1% in de chemohyperthermie 
groep en 64.8% in de BCG-groep. Dit verschil grensde aan significantie met een 
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p-waarde van 0.08. In de Per-Protocol analyse, waarin alle patiënten werden 
geanalyseerd met ≥6 behandelingen, werd een 2-jaars recidiefvrije overleving 
gezien van 81.8% in de chemohyperthermie groep en 64.8% in de BCG-groep. 
Dit verschil was significant met een p-waarde van 0.02. Progressie naar 
spierinvasieve blaaskanker werd gezien in <2% van de patiënten. De complete 
respons na 3 maanden in CIS-patiënten, de secundaire uitkomstmaat van deze 
studie, was hoog met 88.9% in de chemohyperthermie groep en 85.7% in de 
BCG-groep, zonder een significant verschil tussen beide groepen. Er werden 
geen nieuwe bijwerkingprofielen geïdentificeerd.
Verscheidene internationale studies beschrijven de potentieel goede effecten 
van chemohyperthermie in niet-spierinvasieve blaaskanker patiënten. Er 
bestaat echter nog altijd veel onduidelijkheid over het werkingsmechanisme 
van chemohyperthermie. Bovendien is er een groep patiënten die niet reageert 
op chemohyperthermie, die niet kan worden onderscheiden van andere niet-
spierinvasieve blaaskankerpatiënten. In Hoofdstuk 4 zijn de cytokine reacties 
in urine onderzocht bij patiënten die intravesicale chemotherapie ondergingen 
in verband met niet-spierinvasieve blaastumoren. In deze pilot-studie waren 
er twee groepen opgesteld: groep 1 onderging intravesicale chemotherapie 
met hyperthermie van blaas. Groep 2 kreeg de intravesicale chemotherapie 
toegediend zonder hyperthermie (de controle groep). Het doel van de studie was 
om verschillen in cytokine concentraties aan te tonen tussen de twee groepen, 
om op deze wijze meer inzicht te krijgen in de moleculaire mechanismen die 
chemohyperthermie bewerkstelligt in de blaas. Cytokine concentraties waren 
significant hoger voor MCP-1 en IL-6, in de chemohyperthermie groep. MDC-
concentraties na de eerste week in de chemohyperthermie subgroep waren 
significant hoger in de patiënten met een goed klinisch effect in vergelijking 
met de MDC-concentratie in de urine van patiënten die niet reageerden 
op chemohyperthermie. Deze laatste bevinding kan waardevol zijn in het 
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individualiseren van chemohyperthermie, waarbij patiënten met een lage MDC-
concentratie in het begin de behandeling sneller kunnen stoppen. Uiteraard is 
deze bevinding het resultaat van een kleine pilot-studie en dient een volgende 
studie met meer patiënten en langere follow-up deze eerste resultaten te 
valideren.
In Hoofdstuk 5 worden de resultaten gepresenteerd van het nieuwe intravesicale 
geneesmiddel TMX-101. TMX-101 is onderdeel van de Toll Like Receptor 
agonisten, die een belangrijke rol spelen in het antimicrobiële milieu en het 
immuunsysteem van het menselijk lichaam. Preklinische studies suggereerden 
goede antitumor effecten van TMX-101, en een vastere substantie van TMX-
101 wordt al toegepast in de behandeling van basaalcelcarcinomen, actinische 
keratose en genitale wratten. In dit proefschrift wordt het ablatieve vermogen van 
TMX-101 onderzocht bij niet-spierinvasieve blaastumoren in een multicentrische 
fase I markerlaesie studie. De primaire uitkomstmaat was complete respons van 
de blaastumoren. Ondanks de veelbelovende resultaten in preklinische studies, 
werd er in deze fase I studie geen complete respons gezien van de markerlaesies. 
Het veiligheidsprofiel van TMX-101 kon wel worden bevestigd. Een nieuwe 
studie met andere doses en/of toedieningschema’s start zeer waarschijnlijk in 
het begin van 2017. Om hiermee definitief het ablatieve effect van TMX-101 aan 
te tonen dan wel uit te sluiten.
Tot slot bediscussiëren we in Hoofdstuk 6 de bovenstaande hoofdstukken in een 
breder perspectief en richten we een korte blik op de toekomstige ontwikkelingen 
in dit onderzoeksgebied. In Hoofdstuk 7 wordt er een samenvatting van het 
gehele proefschrift gegeven. 
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Dankwoord
Het voelt ietwat onwerkelijk, de eerste woorden typen van het dankwoord 
in je eigen proefschrift. Is het dan nu echt af? Ja, het laatste artikel voor dit 
proefschrift is zojuist geaccepteerd. Voor de verwezenlijking van dit proefschrift 
ben ik (alvast) iedereen dankbaar die op zijn of haar manier een bijdrage heeft 
geleverd. Een aantal van deze personen wil ik graag in het bijzonder bedanken:
Prof. dr. J.A. Witjes, beste Fred. Mijn grootste dank gaat uit naar jou. Als 
coassistent heb jij mij opgemerkt als gemotiveerde student. Bij mijn afstuderen 
in mei 2012 was er helaas geen plek binnen jouw onderzoeksgroep, en hierover 
hebben we ook open kunnen praten. Mijn vreugde was des te groter toen je eind 
2012 naar Amersfoort belde met de vraag of ik de volgende promovendus op 
blaaskankergebied wilde worden. Door de jaren heen heb ik je goed leren kennen 
en veel respect gekregen voor je hoogstaande werkzaamheden als clinicus, 
wetenschapper en opleider. Naast onze wetenschappelijke samenwerking heb 
ik ook erg genoten van de etentjes bij jullie thuis. Etentjes die werden geïnitieerd 
om mijn wetenschappelijke vorderingen te bespreken, maar als ik na een lange 
avond op de fiets naar huis sprong hadden we het over van alles gehad, behalve 
de wetenschap. Fred, ik heb enorm veel van je mogen leren en ben je erg 
dankbaar voor de mogelijkheden die je hebt geboden in mijn promotietraject. 
Ook in de nabije toekomst mag ik gelukkig nog veel van je leren als opleider van 
de Urologie aan het Radboudumc.
Dr. A.G. van der Heijden, beste Toine. De rol als copromotor mag niet worden 
onderschat. Mijn wetenschappelijke schrijfvaardigheden zijn door jouw kritische 
blik behoorlijk bijgeschaafd. Mijn dank is groot voor het eindeloos nalezen en 
corrigeren van mijn conceptstukken. Hopelijk blijft onze samenwerking in de 
toekomst ook van kracht.
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Dr. E. Oosterwijk, beste Egbert. De copromotor waar ik als promovendus altijd 
zonder afspraak binnen kon lopen. Jouw heldere en kritische blik op de wetenschap 
heeft mij erg veel geholpen. Manuscripten die ik in concept toestuurde, kreeg ik 
de volgende dag terug met enkele cruciale wijzigingen die het geheel naar een 
hoger niveau tilde. Van deze revisies en onze gedachtewisselingen heb ik veel 
mogen leren, waarvoor mijn dank.
De leden van de manuscriptcommissie prof. dr. L.F.A.G. Massuger, prof. dr. 
Th.M. de Reijke, dr. A.J.A. Bremers wil ik danken voor het beoordelen van dit 
proefschrift. 
Prof. dr. J.A. Schalken, beste Jack, wetenschappelijk hebben we geen projecten 
gedeeld, desalniettemin heb ik mijzelf op jouw experimentele urologie afdeling 
ontzettend welkom gevoeld. Uiteraard zijn mijn herinneringen onlosmakelijk 
verbonden aan de gezellige koffiemomenten in de ochtend, alwaar menig 
wereldvraagstuk door ons werd bediscussieerd; en vaak ook direct opgelost.
Ook wil ik graag van het moment gebruik maken om alle studiepatiënten te 
danken voor hun medewerking en tijd om bij te dragen aan de wetenschappelijke 
ontwikkelingen van dit proefschrift.
Veel dank aan de medewerkers van de afdeling experimentele urologie. 
Complimenten voor de (werk)sfeer die jullie met elkaar weten te creëren. Een 
sfeer waarin ik me vanaf de eerste dag in thuis voelde. Miriam, jij in het bijzonder, 
dank voor alle hulp en gezelligheid. Pipetteren kun je leren!
Dank aan mijn collega arts-onderzoekers Siebren, Luc, Stijn, Boy, Esther, Ruben, 
Tim, Marlène en Rianne. Boy en Luc dank voor alle kroegwijsheid die we met 
elkaar hebben gedeeld en opgedaan buiten kantooruren. Zaken die men niet 
kan leren aan een universiteit.
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Guido Bastiaens en Maurits van der Meer, a.k.a. de muggendokters. De kamer 
die wij deelden heeft nog nooit een dusdanig geoliede machine gekend als de 
onze. Ze hebben het er nog over.
Overige urologische collegae: Max, Allon, Allert, Rianne, Jos, Dick, Hans. 
Een bijzonder woord van dank aan Max voor het begeleiden van mijn 
wetenschappelijke stage. Veel succes gewenst aan Hans; de nieuwe blaaskanker 
promovendus.
Stafleden en medewerkers van de afdeling urologie van het Radboudumc. Mede 
dankzij jullie heb ik erg genoten van mijn tijd als arts-onderzoeker. Veel dank 
aan de Synergo-zusters Wendy, Moniek en Diana voor alle ondersteuning en 
gezelligheid tijdens de Synergo-poli. Hilde, de Synergo-poli wordt nu al een jaar 
door jou probleemloos draaiende gehouden. Leuk dat ik je wegwijs heb mogen 
maken in de wondere wereld van Synergo.
Collega’s van het Rijnstate Ziekenhuis te Arnhem, dank voor de leerzame, maar 
zeker ook gezellige, chirurgische vooropleiding. 
Oud-collega’s uit Amersfoort, dank voor de fijne en leerzame tijd tijdens mijn 
ANIOS-werkzaamheden in de oude Lichtenberg.
Lieve jaargenoten, in 2005 bij elkaar gezet door beslissingen waar wij zelf weinig 
invloed op hadden en sindsdien gegroeid tot een hechte vriendengroep. Onze 
jaarband heeft mijn studententijd naar een niveau getild die ik anders niet had 
mogen meemaken. Van vele momenten overheerst de waas van geluk boven 
de daadwerkelijke herinnering. Mijn eeuwige dank gaat uit naar de relativering 
en kritische blik van jullie op de medische wereld. Jullie herinneren me telkens 
weer aan het feit dat er meer bestaat dan de geneeskunst. Op naar het volgende 
jaarweekend!
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Stijn Nelen, Jan Burgemeester, Jan van Zelst, Eibert Buitenhuis, elkaar leren 
kennen in de beginjaren van de studie en nog altijd veel contact met elkaar. Een 
waardevolle vriendengroep, ook nu we verder uit elkaar wonen. Weekendjes 
zoals in de Ardennen zijn zeker voor herhaling vatbaar.
Daan Langbroek en Pieter-Jan Stöteler, met jullie heb ik in totaal zes jaar Die 
Tirollerhütte gedeeld aan de Derde Walstraat 120. Allebei huisgenoten die ik 
me niet beter had durven wensen en waar ik naast mijn wetenschappelijke 
ontwikkeling ook vele andere zaken heb mogen leren. Het genieten van de 
zon in de grote ramen, de gehorigheid, de zolder, de drank, de brand in de 
onderbroekjes-kroonluchter, de stank, de zooi, de X-box en natuurlijk de 
Vierdaagsefeesten. Een tijd die ik nooit zal vergeten.
Erik en Stijn. Ik vind het fantastisch dat jullie aan mijn zijde staan als paranimfen 
tijdens deze bijzondere dag. Nog een laatste keer alle drie tegelijk in rokkostuum, 
net als in onze geweldige studentenjaren. Alleen deze keer voor een iets ander 
publiek en met een rokwit dat ook daadwerkelijk nog wit is.
Kyra, vrienden voor het leven vanaf jongs af aan. Wellicht niet een directe 
bijdrage aan mijn proefschrift, maar altijd geïnteresseerd en natuurlijk de 
prachtige momenten met Lisa, jou en Ton die onbetaalbaar zijn. Op naar de 
volgende Waalstrand-BBQ!
Lieve mama en papa, jullie hebben mij de mogelijkheid geboden mij te 
ontwikkelen tot wie ik ben. Altijd heb ik mij gesteund gevoeld in de richting die 
ik koos. Ook toen ik besloot een jaar te stoppen met mijn studie om te reizen. 
Lieve zus, lieve broer, de warme en ontspannen sfeer die wij met elkaar hebben 
is mij erg dierbaar. Dank voor alle interesse en nuchtere feedback over dit zeer 
gespecialiseerde onderwerp. 
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Lieve Lisa, zonder jou was dit proefschrift er niet geweest. De continue steun 
in mijn beslissingen en jouw betrokkenheid hebben ervoor gezorgd dat ik dit 
dankwoord mag schrijven. Jij hebt nooit getwijfeld aan mijn capaciteiten en 
doorzettingsvermogen en daarvoor ben ik je erg dankbaar. Je maakt mij de 
gelukkigste man ter wereld en door jou weet ik dat er meer is dan werken alleen. 
Ik geniet intens van onze momenten samen en als kroon op ons samenzijn, 
vieren wij de liefde in augustus. Wat is het toch heerlijk en makkelijk om veel 
van jou te kunnen houden! 
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